US20030051728A1 - Method and device for delivering a physiologically active compound - Google Patents
Method and device for delivering a physiologically active compound Download PDFInfo
- Publication number
- US20030051728A1 US20030051728A1 US10/057,198 US5719801A US2003051728A1 US 20030051728 A1 US20030051728 A1 US 20030051728A1 US 5719801 A US5719801 A US 5719801A US 2003051728 A1 US2003051728 A1 US 2003051728A1
- Authority
- US
- United States
- Prior art keywords
- compound
- gas
- vaporization
- heating
- air
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
- A61M11/044—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical with electrodes immersed in the liquid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/1075—Preparation of respiratory gases or vapours by influencing the temperature
- A61M16/109—Preparation of respiratory gases or vapours by influencing the temperature the humidifying liquid or the beneficial agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B17/00—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups
- B05B17/04—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B7/00—Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas
- B05B7/16—Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas incorporating means for heating or cooling the material to be sprayed
- B05B7/1686—Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas incorporating means for heating or cooling the material to be sprayed involving vaporisation of the material to be sprayed or of an atomising-fluid-generating product
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
- A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
- A61M2016/0039—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3606—General characteristics of the apparatus related to heating or cooling cooled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3653—General characteristics of the apparatus related to heating or cooling by Joule effect, i.e. electric resistance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/368—General characteristics of the apparatus related to heating or cooling by electromagnetic radiation, e.g. IR waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
Definitions
- This invention relates to a method and a device for volatilizing a physiologically active compound and administering the volatilized compound in the form of an aerosol to a patient.
- An aerosol is defined as an assembly of liquid or solid particles suspended in a gaseous medium. (See Aerosol Measurement, Willeke and Baron, Wiley-lnterscience 1993.) It is known that aerosols of appropriate particle size, can be used to deliver drugs to organs and tissues such as the lung and mucosa. (See Gonda, I., “Particle Deposition in the Human Respiratory Tract,” The Lung: Scientific Foundations, 2 nd ed., Crystal, West, et al. editors, Lippincott-Raven Publishers, 1997).
- a problem in generating an aerosol is maintaining the purity of a compound being administered into the lung, as an aerosol. This is a critical issue that must be addressed before inhalation delivery of a compound to humans will be acceptable to regulatory agencies, physicians and patients. Any compound administered to humans must meet strict purity requirements regulated by government agencies and industry. For example, the United States Food and Drug Administration mandates purity requirements for pharmaceutical materials sold in the United States to protect the health of consumers of those products. Purity requirements are often material specific. Maximum impurity or degradant levels are specified at the time of manufacture of compounds as well as at the time of their consumption or administration. Any aerosolization device or process that will be utilized for pharmaceutical applications, therefore, must deliver materials meeting purity requirements. Mechanisms of chemical degradation that might occur during vaporization and aerosolization, the processes relevant to this invention, are discussed below.
- DPI dry powder inhalers
- the first problem is the manufacturing of the dry powder.
- Some mills used for micronization are known to produce heat, which can cause degradation of the drug, and tend to shed metallic particles as contaminants.
- Following milling it is often necessary to mix the drug with a carrier to impart flowability.
- the micronized drug and the drug-excipient mix must be maintained in a dry atmosphere lest moisture cause agglomeration of the drug into larger particles.
- many dry powders grow as they are delivered to the patient's airways due to the high levels of moisture present in the lung. Thus, this approach requires scrupulous attention during milling, blending, powder flow, filling and even administration to assure that the patient receives the proper particle size distribution.
- Nebulizers generate an aerosol from a liquid, some by breakup of a liquid jet and some by ultrasonic vibration of the liquid with or without a nozzle. All liquid aerosol devices must overcome the problems associated with formulation of the compound into a stable liquid state. Liquid formulations must be prepared and stored under aseptic or sterile conditions since they can harbor microorganisms. This necessitates the use of preservatives or unit dose packaging. Additionally solvents, detergents and other agents are used to stabilize the drug formulation. The FDA is increasingly concerned about airway hypersensitivity from these agents.
- PMDI's Pressurized metered dose inhalers, or pMDI's, are an additional class of aerosol dispensing devices.
- PMDI's package the compound in a canister under pressure with a solvent and propellant mixture, usually chlorofluorocarbons (CFC's, which are being phased out due to environmental concerns), or hydroflouroalkanes (HFA's).
- CFC's chlorofluorocarbons
- HFA's hydroflouroalkanes
- pMDI's particle size is hard to control and has poor reproducibility leading to uneven and unpredictable bioavailability.
- pMDIs are inefficient because a portion of the dose is lost on the walls of the actuator, and due to the high speed ejection of the aerosol from the nozzle, much of the drug impacts ballistically on the tongue, mouth and throat and never gets to the lung.
- reactions may involve only the parent compound or may involve other chemicals such as oxygen in air and materials in the surfaces to which the compound may be exposed. Reactions may be single step or multiple steps, leading to the potential of many degradation products. Activation energies of these reactions depend on molecular structures, energy transfer mechanisms, transitory configurations of the reacting molecular complexes, and the effects of neighboring molecules. Frequently, on the practical macroscopic scale, a drug dose may suffer from many degradation reactions in progress at the same time. Because of this complex potential for degradation, drug substances are often stored at or below room temperature.
- the present invention overcomes the foregoing disadvantages and problems, making it possible to produce pure aerosols of degradable compounds wherein the particle size is stable and selectable.
- Embodiments of the present invention are directed to a method and a device for generating and delivering an aerosol formed through vaporization of a compound with real or potential physiological activity.
- a physiologically active compound with real or potential physiological activity is defined here as a chemical compound or mixture of compounds that alters affects, treats, cures, prevents or diagnoses a disease after it is administered to the mammalian body.
- the compound with real or potential physiological activity will be referred to hereafter as the compound or as the drug. Examples would include medicinal drugs, or “pro-drugs” (substances converted into drugs within the body), that would be administered for the treatment, cure, or diagnosis of diseases.
- the method of the present invention for generating an aerosol comprises the steps:
- a desired particle size is typically from molecular to about 10 microns in diameter. Aerosols having “ultra fine” (0.01 to 0.1 micron) and “fine” (1 to 3 micron) particle sizes are known to provide efficient and effective systemic delivery through the lung. Current literature suggests that the middle size range of particles, between ultra fine and fine, i.e., between 0.1 and 1 micron in size, are too small to settle onto the lung wall and too massive to diffuse to the wall in a timely manner. Thus, a significant number of such particles are removed from the lung by exhalation, and thus are not involved in treating disease (see Gonda).
- This method creates a mixture of vapor and gas for administration to the patient.
- air for the purposes of controlling particle size the terms “air”, “mixing gas”, “dilution gas” and “carrier gas” are interchangeable.
- FIG. 1 is a schematic diagram of the overall system for conducting experiments using a laboratory device of the present invention
- FIG. 2 is a top, right end and front perspective view of the actual laboratory device depicted in FIG. 1;
- FIG. 3 is a partial cross-sectional and partial schematic side view of the device shown in FIG. 2;
- FIG. 4 is a partial cross-sectional and partial schematic end view of the device shown in FIG. 2;
- FIG. 5 is a partial cross-sectional and partial schematic top view of the device shown in FIG. 2;
- FIG. 6 is a schematic cross-sectional side view of an alternate embodiment of the device of the present invention using an annunciating device
- FIG. 7 is a top, left end and front perspective views of the removable sub-assembly containing the compound and a movable slide of the device shown in FIG. 2 showing the sub-assembly being mounted within the slide;
- FIG. 8 is a schematic view of the heating element of the embodiment shown in FIG. 2 showing the electric drive circuit
- FIG. 9 is a schematic side view of a second embodiment of the present invention using a venturi tube
- FIG. 10 is a schematic side view of third embodiment of the present invention using a thin-walled tube coated with the compound
- FIG. 11 is a schematic side end view of the embodiment shown in FIG. 10;
- FIG. 12 is a schematic side end view of the embodiment shown in FIG. 10 showing an inductive heating system generating an alternating magnetic field;
- FIG. 13 is a schematic side view of an alternate embodiment of that shown in FIG. 10 using a flow restrictor within the thin-walled tube coated with the compound;
- FIG. 14 is a schematic side view of a fourth embodiment of the present invention using a pressurized gas to flow over the compound;
- FIG. 15 is a schematic end view of the embodiment shown in FIG. 14;
- FIG. 16 is a schematic side view of a fifth embodiment using a re-circulation of a gas over the compound's surface
- FIG. 17 is a schematic side view of a sixth embodiment of the present invention using a tube containing particles coated with the compound
- FIG. 18 is a schematic side view of the embodiment shown in FIG. 17 using a heating system to heat the gas passing over the coated particles;
- FIG. 19 is a schematic side view of a seventh embodiment of the present invention referred to herein as the “oven device”;
- FIG. 20 is a schematic side view of an eighth embodiment of the present invention using gradient heating
- FIG. 21 is a schematic side view of a ninth embodiment of the present invention using a fine mesh screen coated with the compound
- FIG. 22 is a top, right end and front perspective view of the embodiment shown in FIG. 21;
- FIG. 23 is a plot of the rate of aggregation of smaller particles into larger ones
- FIG. 24 is a plot of the coagulation coefficient (K) versus particle size of the compound
- FIG. 25 is a plot of vapor pressure of various compounds, e.g., diphenyl ether, hexadecane, geranyl formate and caproic acid, versus temperature;
- FIG. 26 is a plot of blood levels for both the IV dose and the inhalation dose administered to various dogs during the experiments using the system shown in FIG. 1;
- FIG. 27 is a plot of calculated and experimental mass median diameter (MMD) versus compound mass in the range of 10 to 310 ⁇ g;
- FIG. 28 is a plot of calculated and experimental MMD versus compound mass in the range of 10 to 310 ⁇ g.
- FIG. 29 is a plot of the theoretical size (diameter) of an aerosol as a function of the ratio of the vaporized compound to volume of the mixing gas.
- compounds with real or potential physiological activity can be volatilized without medicinally significant degradation and the resulting vapors controlled to form aerosols with particle sizes useful for the administration of the compound to a patient.
- compounds are volatilized into vapors avoiding medicinally-significant degradation and thus maintaining acceptable compound purity by the steps of (1) heating the physiologically active compound to a temperature for a limited time and (2) under the conditions of step (1), simultaneously passing a gas across the surface of the compound.
- vaporization has not previously been viewed as a reasonable mechanism for the delivery of most pharmaceutical compounds.
- the present invention makes vaporization a practical delivery method in part, by utilizing a flow of gas across the surface of the compound, to create a dynamic situation in which a compound's vapor molecules are swept away from its surface, driving the chemical equilibrium process towards further vaporization.
- this method creates a practical rate of vaporization with only moderate heating.
- 1 mg of nicotine, (boiling point of 247° C./745 mm) was observed to vaporize around 130° C. in less than 2 seconds with a laboratory device of the present invention described in detail in the EXAMPLES below.
- fentanyl which decomposes rapidly at 300° C.
- Vaporization can therefore be accomplished with the embodiments of this invention at practical rates, i.e., in the range of about 0.5 to about 2 mg/second, and at temperatures much below the compounds' boiling points. The ability to vaporize at these reduced temperatures provides a means to lower rates of degradation reactions in many compounds.
- the ability of the present invention to also limit the time during which the compound is exposed to an elevated temperature is also critical. Limiting the exposure time of a compound to temperature is accomplished by rapid heating of a thin film of a deposited compound followed by immediate cooling of the compound vapors as they enter a carrier gas stream. In the preferred embodiments, the compound is moved quickly through a heating/mixing zone to facilitate a rapid temperature rise on the order of 2,000° C./second. Compounds thus reach vaporization temperatures in ten's of milliseconds. Under these conditions, compound molecules quickly escape as vapors from thin layers of deposited compound, and move into a cool carrier gas stream that flows across the surface of the compound. The vapor molecules, thus quickly created, lose their thermal energy when they collide with molecules of the cooler carrier gas.
- the method of the present invention which uses rapid heating to reach vaporization temperatures of compounds, and after vaporization, rapid cooling of the vapor, has been shown to be significant in reducing decomposition, one of the obstacles to generating the desired aerosol.
- Lipophilic substance # 87 for example, decomposed by more than 90% when heated at 425° C. for 5 minutes, but only 20% when the temperature was lowered to 350° C. Decomposition was lowered further to about 12% when the time was decreased to 30 seconds, and to less than 2% when the time was decreased to 10-50 milliseconds. Similarly, 100% of a fentanyl sample decomposed when heated to 200° C.
- the method of this invention also overcomes the second obstacle to generating the desired aerosol by controlling the generated compound vapors so that an aerosol is formed that (1) is comprised of particles within a desired size range and (2) these particles are sufficiently stable so they will retain their sizes within that range during the time necessary to administer the aerosol to a patient.
- Particle size is usually expressed as the equivalent diameter of a spherical particle with the same physical behavior.
- the range of particle sizes in an aerosol is most often described by its mass median diameter (MMD) or mass median aerodynamic diameter (MMAD), and its geometric standard deviation (GSD).
- MMD mass median diameter
- MMAD mass median aerodynamic diameter
- GSD geometric standard deviation
- the method of the present invention forms an aerosol with particles of a desired size range and stability by applying the principle that particle growth can be predicted from the number concentration of the particles in a given volume.
- particles frequently collide and adhere to each other.
- Such a collision and adhesion event creates one particle from two smaller ones.
- these events lead to an increase in mean particle size and a decrease in number concentration.
- the frequency of collisions among particles then decreases, since there are fewer particles available and because the remaining larger particles move more slowly. As a consequence, the rate of particle size growth slows.
- stable particle size can be applied in a practical sense when particle size growth has slowed sufficiently to ensure the purpose of the application.
- a stable particle would be one that exists in the ultra fine or fine size range for the 1 to 3 seconds required for a typical inhalation.
- a particle of the ultra fine or fine size range is produced that is stable for several seconds.
- a predetermined amount of compound in its vapor-state can be mixed into a predetermined volume of a carrier gas in a ratio to give particles of a desired size as the number concentration of the aerosol itself becomes stable.
- a stable number concentration is approximately 10 9 particles/cc.
- the method of the present invention forms the aerosol with particles of a desired size range and stability by controlling the rate of vaporization, the rate of introduction of a carrier gas, and the mixing of the vapors and the carrier gas, thereby manipulating the parameters that govern the physical processes of a compound's condensation and particle aggregation.
- Controlling the ratio of the vaporized compound to the volume of mixing air can be done by a number of methods including: (a) measuring the quantity and regulating the flow rate of the mixing air; and/or (b) regulating the vaporization rate of the compound, e.g. changing the energy transferred to the compound during the heating process or changing the amount of compound introduced into a heating region.
- the site of deposition within the lung can be changed. This can allow targeting of the site of deposition of the compound in the lung and airways.
- a desired particle size is achieved by mixing a compound in its vapor-state into a volume of a carrier gas, in a ratio such that when the number concentration of the mixture reaches approximately 10 9 particles/ml, a “stable” particle size is present.
- the amount of compound and the volume of gas are each predetermined to achieve this ratio.
- FIG. 23 shows the time in seconds it takes for the number concentration of an aerosol to aggregate to half of its original value as a function of the particle concentration. It is a plot of theoretical data calculated from a mathematical model, (See Hinds). For example, a 1.0 mg vaporized dose of a compound with a molecular weight of 200 that is mixed into 1 liter of air will have approximately 3 ⁇ 10 18 molecules (particles) in the liter. This results in a number concentration of 3 ⁇ 10 15 /cc. Extrapolating from FIG. 23, one can see that the time required for the number of particles to halve in this example is less than 10 microseconds. This demonstrates that to insure uniform mixing of the vaporized compound, the mixing must happen in a very short time.
- FIG. 23 shows that when the number concentration of the mixture reaches approximately 10 9 particles/cc, the particle sized will be “stable” for the purpose of drug delivery by inhalation.
- FIG. 23 is for an aerosol having a Coagulation Coefficient (K) of 5 ⁇ 10 ⁇ 16 meters 3 /second.
- K Coagulation Coefficient
- Table 1 gives the K values for various particle sizes.
- K increases, the time required for the aerosol to aggregate from a particular particle size to a larger particle size is reduced.
- Table 1 and FIG. 24 when the particle is in the ultra fine region, as defined in the BACKGROUND OF THE INVENTION section, the effect of a changing K value tends to accelerate the coagulation process towards 100 nm in size.
- the size of the particle affects its stability.
- the ratio of mass of vaporized compound to the volume of the mixing gas is the controlling condition. By changing this ratio, the particle size can be manipulated (see FIG. 29). However, not all compounds and not all gases, with the same ratio will result in the same particle size distribution (PSD). Other factors must be known to be able to accurately predict the resultant particle size. A compound's density, polarity, and temperature are examples of some of these factors. Additionally, whetheer the compound is hydrophilic or hydrophobic will affect the eventual particle size, because this factor affects an aerosol's tendency to grow by taking on water from the surrounding environment.
- the compound is non polar (or has a weak polarity).
- the compound is hydrophobic or hydrophilic with a mixing gas that is dry.
- the resultant aerosol is at or close to standard temperature and pressure.
- Predicting the particle size would be a simple matter for a given number concentration and amount of the compound, if the GSD is 1. With a GSD of 1, all of the particle sizes are the same size and therefore the calculation of particle size becomes a matter of dividing a compound's mass into the number of particles given by the number concentration and from there calculating the particle size diameter using the density of the compound.
- MMD mass median diameter
- N Number concentration in particles/cc
- MMD mass median diameter (in cm)
- M the mass per unit volume of the aerosol in gms/cc
- MMD 1 /MMD 2 exp[ ⁇ 3/2(1 n ⁇ g2 ) 2 ]
- MMD 1 To calculate MMD 1 , divide the compound's mass into the number of particles and then, calculate its diameter using the density of the compound.
- MMD 1 (6C/ ⁇ NV ⁇ ) 1 ⁇ 3 for an aerosol with a GSD of 1
- N Number concentration in particles/cc (as before)
- V volume of the mixing gas in cc
- MMD 2 (6C/ ⁇ NV ⁇ ) 1 ⁇ 3 [exp[ ⁇ 3/2(1n ⁇ g2 ) 2 ], measured in centimeters.
- a resultant MMD can be calculated from the number concentration, the mass of the compound, the compound density, the volume of the mixing gas, and the GSD of the aerosol.
- an aerosol of the desired particle size range is created by controlling the volume of air (or other gas) within which the compound is allowed to aggregate.
- air or other gas
- a large ratio of mixing gas to compound vapor is used.
- it is necessary to reduce the volume of the initial mixing gas which leads to an increase in the concentration of the compound, which in turn results in a greater particle size growth before a desired number concentration is reached and aggregation slows.
- this initial mixing stage can be, if needed, accomplished in the presence of an inert gas to reduce decomposition resulting from oxidation.
- the required vaporization rate is different depending on the particle size one wishes to create. If the particle size is in the ultra fine region, then the compound, once vaporized, must be mixed, in most cases, into the largest possible volume of air. This volume of air is determined from lung physiology and can be assumed to have a reasonable upper limit of 2 liters. If the volume of air is limited to below 2 liters (e.g. 500 cc, unless the dose is exceedingly small, i.e., less that 50 ⁇ g, too large a particle will result and optimum lung deposition will not be possible.
- 2 liters e.g. 500 cc
- FIG. 1 The first embodiment of the present invention is shown in FIG. 1 and is the basic device through which the principles cited above have been demonstrated in the laboratory. This device is described in detail in the EXAMPLES.
- the use of a reduced airway cross section increases the speed of the air across the compound's surface to about 10 meters/second. If complete mixing is to happen within 1 millisecond then the distance the gas and vaporized mixture must travel to achieve complete mixing must be no longer than 10 millimeters. However, it is more desirable for complete mixing to happen before the compound has aggregated to a larger size, so a desirable mixing distance is about 1 millimeter or less.
- an ultra fine aerosol is generated by allowing air to sweep over a thin film of the compound during the heating process. This allows the compound to become vaporized at a lower temperature due to the lowering of the partial pressure of the compound near the surface of the film.
- FIGS. 14 - 15 The fourth embodiment shown in FIGS. 14 - 15 is directed to placing the compound on a slide that moves within an airway along the direction of air travel and simultaneously passing a pressurized gas over the compound as it is vaporized. Upon vaporization the compound is free to move down the airway and to the patient.
- a volume of gas is re-circulated over the surface of the heated compound to aid in its vaporization.
- the resulting aerosol is then combined with additional gas to rapidly cool the mixture before delivery to a patient.
- gas is passed into a first tube and over discrete substrate particles having a large surface area to mass ratio and coated with the compound.
- the particles are heated as shown in FIG. 17 to vaporize the compound or the gas is heated and the heated gas vaporizes the compound as shown in FIG. 18.
- the gaseous mixture from the first tube is combined with the gas passing through second tube to rapidly cool the mixture before administering to a patient.
- the compound is introduced into the gas as a pure vapor. This involves vaporizing the compound in an oven or other container and then injecting the gaseous mixture into an air or other gas stream through one or more mixing nozzles.
- the eighth embodiment shown in FIG. 20 is a thermal gradient device that is similar to the preferred embodiment used in the laboratory experiments.
- This device also has a moving heating zone without any moving parts, accomplished by establishing a heat gradient that transverses from one end of the device to the other over time. As the heating zone moves, exposed portions of the compound are sequentially heated and vaporized. In this manner the vaporized compound can be introduced into a gas stream over time.
- the ninth embodiment shown in FIGS. 21 - 22 is the screen device and is preferred for generating a fine aerosol.
- air is channeled through a fine mesh screen upon which the drug to be administered to the patient has been deposited.
- the embodiments above can create aerosols without significant drug decomposition. This is accomplished while maintaining a required vaporization rate for particle size control by employing a short duration heating cycle. An airflow over the surface of the compound is established such that when the compound is heated and reaches the temperature where vaporization is first possible, the resulting compound vapors will immediately cool in the air. In the preferred embodiments, this is accomplished by extending the increased velocity and mixing region over an area that is larger than the heating zone region. As a result, precise control of temperature is not necessary since the compound vaporizes the instant its vaporization temperature is reached. Additionally because mixing is also present at the point of vaporization, cooling is accomplished quickly upon vaporization.
- a patient is directed to breathe in a way that maximizes deposition of the drug in the lung.
- This kind of breathing usually involves a full exhalation, followed by a deep inhalation sometimes at a prescribed inhalation flow rate range, e.g., about 10 to about 150 liters/minute, followed by a breath hold of several seconds.
- the aerosol is not uniformly distributed in the air being inhaled, but is loaded into the early part of the breath as a bolus of aerosol, followed by a volume of clean air so that the aerosol is drawn into the alveoli and flushed out of the conductive airways, bronchi and trachea by the volume of clean air that follows.
- a typical deep adult human breath has a volume of about 2 to 5 liters.
- delivery of the drug bolus should be completed in the first 1-11 ⁇ 2 liters or so of inhaled air.
- a compound must be vaporized in a minimum amount of time, preferably no greater than 1 to 2 seconds.
- the compound needs to be vaporized over approximately 1 to 2 seconds for creation of particles in the ultra fine range.
- the compound needs to be mixed into the air or other gas at a consistent rate to have a consistent and repeatable particle size.
- the parameters of the design for one of the preferred embodiments shown in FIGS. 2 - 5 , 7 and 8 are the result of meeting and balancing the competing requirements listed above.
- One especially important requirement for an ultra fine aerosol is that a compound, while needing to be vaporized within at least a 1-second period, also needs to have each portion of the compound exposed to a heat-up period that is as brief as possible.
- the compound is deposited onto a foil substrate and an alternating magnetic field is swept along a foil substrate heating the substrate such that the compound is vaporized sequentially over no more than about a one second period of time. Because of the sweeping action of the magnetic field, each segment of the compound has a heat-up time that is much less than one second.
- the compound is laid down on a thin metallic foil.
- stainless steel alloy of 302, 304, or 316
- Other foil materials can be used, but it is important that the surface and texture of the material is such that it is “wetted” by the compound when the compound is in its liquid phase, otherwise it is possible for the liquid compound to “ball” up which would defeat the design of the device and significantly change the volatilizing parameters. If the liquid compound “balls” up, the compound can be blown into and picked up by the airflow without ever vaporizing. This leads to delivery of a particle size that is uncontrolled and undesirable.
- Stainless steel has advantages over materials like aluminum because it has a lower thermal conductivity value, without an appreciable increase in thermal mass. Low thermal conductivity is helpful because heat generated by the process needs to remain in the immediate area of interest.
- Exemplary compounds that can be vaporized in accordance with the present invention include cannabinoid extracts from cannabis, THC, ketorolac, fentanyl, morphine, testosterone, ibuprofen, codeine, nicotine, Vitamin A, Vitamin E acetate, Vitamin E, nitroglycerin, pilocarpine, mescaline, testosterone enanthate, menthol, phencaramide, methsuximide, eptastigmine, promethazine, procaine, retinol, lidocaine, trimeprazine, isosorbide dinitrate, timolol, methyprylon, etamiphyllin, propoxyphene, salmetrol, vitamin E succinate, methadone, oxprenolol, isoproterenol bitartrate, etaqualone, Vitamin D3, ethambutol, ritodrine, omoconazole, ***e, lomustine,
- the present invention has unique advantages as a means of delivering drugs by inhalation to the human body.
- the FDA has expressed concern about airway hypersensitivity due to inhalation products (See G. Poochikian and C. M. Bertha, “Inhalation drug product excipients controls: significance and pitfalls” presented at RDD VII, 2000).
- the method and device of the present invention are capable of delivering pure drug vapor to the lung without the simultaneous delivery of formulation ingredients, which oftentimes comprise a significant portion of the mass delivered to the patient when other drug delivery methods and devices are utilized.
- Formulation ingredients often include propellants such as chlorofluorohydrocarbons, solvents such as ethanol, detergents such as Polysorbate 80, preservatives such as benzalkonium chloride or carrier particles such as lactose.
- propellants such as chlorofluorohydrocarbons, solvents such as ethanol, detergents such as Polysorbate 80, preservatives such as benzalkonium chloride or carrier particles such as lactose.
- the present invention has the advantage of not introducing such excipient molecules into the delicate tissues of the lungs.
- the ability to deliver pure drug is especially advantageous for drugs that must be administered chronically.
- This invention allows for the administration of water insoluble drugs to a mammal without the need for excipients or injection. This can be advantageous in treating diseases of the eye, mucosa, skin and broken-skin.
- Another advantage comes from the ability of the present invention to produce an ultra fine aerosol. Approximately 50,000 times as many particles exist within a volume of ultra fine aerosol as exists in the same mass of a fine aerosol. Since each particle deposits on the membrane of the lung, a correspondingly greater number of deposition sites are created in the lungs and at each site less material has to be dissolved and transported into the blood stream. This may be important for improving the rate of absorption and thus the bioavailabilty of compounds, e.g., lipophilic compounds, and large molecules such as proteins, peptides and DNA.
- compounds e.g., lipophilic compounds, and large molecules such as proteins, peptides and DNA.
- ADME device 1 Absorption/Distribution/Metabolism/Excretion (ADME) device 1 , was designed to deliver an experimental dose of fentanyl between 20 ⁇ g and 500 ⁇ g, in a range of ultra fine particle sizes, in about 800 cc of air to a 10 kg dog.
- the lung volume of each dog under experimentation was approximately 600-700 cc and the device was designed to deliver the compound to the lung in the first half of the inhalation. Because of the value of these parameters, ADME device 1 can be considered a 1 ⁇ 4 scale device for administering a dose to a human. It is believed that scaling the device to work for human subjects involves mainly increasing the airflow through the device.
- the two main obstacles, decomposition and particle size control were addressed by moving a substrate that had the compound deposited on it into a heating/vaporization/mixing zone.
- the substrate material which had been chosen in part for its electrical and thermal properties, was moved into an alternating magnetic field, which also coincided with a region of restricted cross-sectional area and mixing geometry.
- the alternating magnetic field induced an electrical current in the substrate and because of the substrate's electrical resistance resulted in a rapid temperature rise, which in turn vaporized the compound.
- the temperature rise occurred in a region where, because of the restriction of the cross- sectional area of the air channel, there was an increase in the air speed across the surface of the compound.
- the increased airflow acted to “sweep” away any compound vapors above the film of compound, which in turn lowered the partial pressure of the compound and increased the rate of vaporization.
- the temperature rise was also in a region where the geometry of the passage had been designed to promote rapid mixing of the vaporized compound into the air. This rapid mixing helped overcome the two noted obstacles in two ways. First, because of the rapid mixing there was a more uniform distribution of the compound into the air. This gave rise to a small distribution of particle sizes, which in turn insured a consistent and small particle size. Second, because rapid mixing occurred, the vaporized compound was rapidly cooled by exchange of its kinetic energy with kinetic energy of the cooler carrier air; which reduced decomposition.
- the time frame of the introduction of the compound into the heating/vaporization/mixing zone was designed to vaporize the compound into a volume of air that was suitable for both the volume required by lung anatomy (600-700 cc) for the dog and the volume needed to control the ratio of the compound to the air, and thereby to control particle size.
- some of the functional limits for this device were defined by lung capacity as well as the requirements for dilution of the aerosol. Lung capacity limits the total amount of drug that can be suspended in the inhaled air at a given concentration.
- the ADME device 1 as shown in FIG. 1 is operably connected to flow meter 4 .
- a TSI 4100 flow meter was used as the flow measuring equipment.
- the readings from flow meter 4 were fed to the electronics within chassis 8 shown in FIG. 2.
- flow meter 4 is shown in FIG. 1 within a dotted line to indicate housing 10 .
- Device controller 20 includes Chembook model # N30W laptop computer having actuator switch 22 (FIG. 3) and National Instruments I/O Board (model #SC2345) that interfaces with computer 20 to control ADME device 1 and to control the recording of all data collected during the experiments.
- a software program to carry out these functions was developed using National Instruments' Labview software program. Connection between device 1 and the I/O board was accomplished with a DB25 cable (not shown). A standard “off the shelf” Condor F15-15-A+ power supply (not shown) delivered power to device 1 .
- Inhalation controller 30 was used to control the rate and volume of inhalation through device 1 into the anesthetized dog through an endotracheal tube 34 . Controller 30 had a programmable breath hold delay, at the end of which, exhaust valve 40 in exhaust line 42 opened and the dog was allowed to exhale. Filter 50 in line 42 measured the amount of exhaust and its composition to monitor any exhaled drug.
- the source air through inlet line 54 , inlet valve 58 , flow meter 4 and inlet orifice 59 was from a compressed air cylinder (not shown).
- the dose of compound 60 was deposited onto thin, stainless steel foil 64 so that the thickness of compound 60 was less than 10 microns.
- compound 60 was deposited by making a solution of the compound with an organic solvent. This mixture was then applied to the foil substrate with an automated pump system. The size of the entire foil 64 was 0.7 by 2.9 inches and the area in which compound 60 was deposited was 0.35 by 1.6 inches.
- Stainless steel (alloy of 302 or 304) foil 64 having a thickness of 0.004 inches was used for foil 64 .
- Other foil materials can be used but stainless steel has an advantage over other materials like aluminum in that it has a much lower thermal conductivity value, while not appreciably increasing the thermal mass.
- a low thermal conductivity is helpful because the heat generated in foil 64 should stay in the area of interest, i.e. the heating/vaporization zone 70 .
- Foil 64 needs to have a constant cross section, because without it the electrical currents induced by the heater will not be uniform.
- Foil 64 was held in frame 68 , made so that the trailing edge of foil 64 had no lip on movable slide 78 and so compound 60 , once mixed with the air, was free to travel downstream as seen in FIG. 7.
- Frame 68 was made of a non-conductive material to withstand moderate heat (200° C.) and to be non-chemically reactive with the compound.
- the material for frame 68 was Delrin AF, a copolymer of acetal and Teflon.
- Sub-assembly 80 shown in FIG. 7 consists of frame 68 having foil 64 mounted therein and with compound 60 deposited on foil 64 .
- Sub-assembly 80 was secured within movable slide 84 by setting each of the downstream ends of frame 68 that were tapered to abut against small rods 86 protruding from each downstream end of slide 78 , as shown in FIG. 7.
- Slide 78 was driven by stepper motor 88 that moved sub-assembly 80 containing compound 60 along the axis of device 1 . This, in turn, moved stainless steel foil 64 through an alternating magnetic field. It is preferable for the magnetic field to be confined within heating/vaporization zone 70 as in this laboratory embodiment.
- Ferrite 90 was used to direct the magnetic field and was placed approximately 0.05 inches below foil 64 .
- heated area 70 was approximately 0.15 by 0.4 inches, with the smaller dimension along the direction of travel from left to right, i.e. from the upstream to the downstream ends of device 1 , and the large dimension across the direction of travel, i.e., the width of device 1 .
- Stainless steel foil 64 functions as both a substrate for the drug to be delivered to the subject and the heating element for the vaporization of the drug.
- Heating element 64 was heated primarily by eddy currents induced by an alternating magnetic field.
- the alternating magnetic field was produced in ferrite toroid 90 with slit 94 , which was wrapped with coil 98 of copper magnet wire.
- a ferrite toroid from the Fair-Rite Company was used.
- the slit was 0.10 inch wide.
- the alternating frequency of the field was limited to below 1 MHz. In this laboratory device, a frequency between 100 and 300 kHz was used.
- alternating magnetic field lines 100 pass through foil 64 an alternating electric field was induced following Faraday's Law of Induction. The electric field caused eddy currents in the foil according to Ohm's law. The current moving through the intrinsic resistance of the foil generated the heat.
- ⁇ o is the permittivity of free space (8.85 ⁇ 10 ⁇ 12 farad/meter)
- c is the speed of light (3 ⁇ 10 8 meters/second)
- ⁇ is the conductivity of the foil (1.38 ⁇ 10 6 1/ohm-meters for stainless steel)
- ⁇ is the frequency of the alternating magnetic field in radians/second.
- the location and geometry of the eddy currents are also important since they determine where foil 64 will be heated. Since magnetic field fringe lines 100 pass through foil 64 twice, once leaving ferrite toroid 90 and once returning, two rings of current were produced, and in opposite directions. One of the rings was formed around magnetic field lines 100 that leave toroid 90 and the other ring formed around magnetic field lines 100 that return to the toroid. The rings of current overlapped directly over the center of slit 94 . Since they were in opposite directions, they sum together. The greatest heating effect was produced over the center of slit 94 .
- Slide 84 and its contents were housed in airway 102 made up of upper airway section 104 and lower airway 108 shown in FIG. 3.
- Upper airway section 104 was removable and allowed the insertion of movable slide 84 and then sub-assembly 80 of frame 78 and foil 64 with compound 60 on it and the removal of sub-assembly 80 after the dose had been administered.
- Lower airway section 108 was mounted on top of chassis 8 that housed the electronics, magnetic field generator 110 , stepper motor 88 and position sensors (not shown). Mounted in upper airway section 104 was upstream passage 120 and inlet orifice 59 that coupled upper airway section 104 to flow meter 4 .
- the readings from the flow meter 4 were fed to the electronics housed in chassis 8 . Additionally, at the downstream end of airway passage 102 was outlet 124 connected to mouthpiece 126 . Under test conditions, air was pulled through the mouthpiece 126 through airway tube 102 and inlet orifice 59 . During administration of compound 60 to the dog, when joined to the system, air was forced through flow meter 4 , inlet line 54 , airway tube 102 , and outlet 124 into the dog.
- a pyrometer at the end of TC2 line 130 was located within airway 102 and was used to measure the temperature of foil 64 . Because of the specific geometry of ADME device 1 , the temperature reading of foil 64 was taken after heating zone 70 . Calibration of the thermal decay between heating zone 70 and the measurement area was required. Temperature data was collected and used for quality control and verification and not to control any heating parameters.
- a second temperature sensor was located at the end of TC 1 line 132 in outlet 124 and was used to monitor the temperature of the air delivered to the dog.
- removable airway section 140 contained a restricted cross-sectional area along with specific mixing geometry mounted in upper airway section 104 .
- airway 140 lowered the roof of upper airway section 104 to within 0.04 inch of foil 64 .
- airway section 140 contained 31 steel rods (not shown) 0.05 inches in diameter. These rods were oriented perpendicular to the foil and extended from the “roof”, i.e., the top of upper airway section 104 , to within 0.004 inches of the foil.
- the rods that were placed in a staggered pattern had sharp squared off ends, which caused turbulence as the air was draw around them. Rapid, highly turbulent movement of mixing air resulted, which assured complete mixing of the vapor with the air passing through the device.
- FIG. 9 schematically represents device 150 , the second embodiment of the present invention, in which the cross-sectional area was also restricted along the gas/vapor mixing area.
- venturi tube 152 within housing 10 having inlet 154 , outlet 156 and throat 158 between inlet 154 and outlet 156 was used to restrict the gas flow through venturi tube 152 .
- Controller 160 was designed to control the flow of air passing through valve 164 based on readings from the thermocouple 168 of the temperature of the air as a result of heater 166 .
- Airway section 140 was located directly over heating zone 70 and created a heating/vaporization/mixing zone. Prior to commencing aerosol generation, slide 78 was in the downstream position. Slide 78 , with its contents, was then drawn upstream into this heating/vaporization/mixing zone 70 as energy was applied to foil 64 through the inductive heater system described in detail below.
- the device of the present invention can be equipped with an annunciating device.
- One of the many functions for the annunciating device is to alert the operator of the device that the compound is not being vaporized or is being improperly vaporized.
- the annunciating device can also be used to alert the operator that the gas flow rate is outside a desired range.
- Annunciating device 170 with on-off switch 174 is schematically represented in FIG. 6 for use with hand held device 180 .
- a signal from annunciating device 170 would alert the patient to adjust the inhalation rate to the desired range.
- controller 160 would be connected to annunciating device 170 to send the necessary signal that the flow rate was not within the desired range.
- the induction drive circuit 190 shown in FIG. 8 was used to drive the induction-heating element of ADME device 1 .
- the purpose of circuit 190 was to produce an alternating current in drive coil 98 wrapped around ferrite core 90 .
- Circuit 190 consisted of two P-channel transistors 200 and two N-channel MOSFET transistors 202 arranged in a bridge configuration. MOSFET transistors 200 and 202 connected to clock pulse generator 219 were turned on and off in pairs by D-type flip-flop 208 through MOSFET transistor drive circuit 210 .
- D-type flip-flop 208 was wired in such a way as to cause the Q output of the flip-flop to alternately change state with the rising edge of the clock generation signal.
- One pair of MOSFET transistors 200 was connected to the Q output on D-type flip-flop 208 and the other pair, 202 , is connected to the Q-not output of flip-flop 208 .
- Q was high (5 Volts)
- a low impedance connection was made between the D.C. power supply (not shown) and the series combination of drive coil 98 and the capacitor through the pair of MOSFET transistors 200 controlled by the Q output.
- D-type flip-flop 208 changed state and Q-not was high, the low impedance connection from the power supply to the series combination drive coil 98 and capacitor 220 was reversed. Since flip-flop 208 changes state on the rising edge of the clock generation signal, two flip-flop changes are required for one complete drive cycle of the induction-heating element.
- the clock generation signal was set at twice the resonant frequency of the series combination of drive coil 90 and capacitor 220 .
- the clock signal frequency can be manually or automatically set.
- Controller 30 signaled controller 20 to start ADME device 1 and to begin collecting data from the two temperature sensors and flow meter 4 .
- device 1 After a pre-programmed delay, device 1 initiated the generation of the aerosol. (Note: there was a delay of about 0.4 seconds between the start of the controller 30 and the start of aerosol generation.)
- controller 30 opened input valve 58 to start forced inhalation to a dog under experimentation.
- Device 1 completed the aerosol generation during the inhalation.
- Controller 30 monitored flow meter 4 and pressure transducer 240 throughout the inhalation and closed off flow at input valve 58 when a pre-specified volume or pressure was met. (Note: the pre-specified pressure is a safety feature to prevent injury to the subject animal. Termination of the breath at the pre-specified volume is the desirable occurrence of the experiment.)
- Controller 30 recorded values for the following: volume dispensed, terminal pressure, duration of air pulse, and average flow rate. Controller 20 continuously recorded at millisecond resolution, input flow rate, exhaust flow rate, foil temperature, mouthpiece temperature, slide position, heater on/off time, and other internal diagnostic electrical parameters.
- Three weight-matched female beagle dogs received fentanyl at a 100 ⁇ g intravenous bolus dose.
- the same dogs received fentanyl UF for Inhalation (100 ⁇ g aerosolized and administered as two successive activations of an ADME device 1 , containing approximately 50 ⁇ g of fentanyl base) at a particle size of 80 nm (MMAD).
- the aerosol was administered to anesthetized dogs via the system schematically represented in FIG. 1, with a target delivered volume of 600-700 ml air, followed by a 5 second breath hold. After dosing, plasma samples for pharmacokinetic analysis were obtained at various time points from 2 min to 24 hr. Fentanyl remaining in the dosing and administration apparatus 1 was recovered and measured. Fentanyl concentrations were measured by using a validated GC method, with a limit of detection of 0.2 ng/ml.
- Plasma pharmacokinetics from this example was compared to intravenous (IV) fentanyl (100 ⁇ g) in the same dogs. Inhalation of fentanyl resulted in rapid absorption (Cmax, maximum concentration in plasma, 11.6 ng/ml and Tmax, maximum time, 2 min.) and high bioavailability (84%). The time course of inhaled fentanyl was nearly identical to that of IV fentanyl. Thus, fentanyl UF for inhalation had an exposure profile that was similar to that of an IV injection.
- fentanyl to demonstrate the utility of the preferred embodiment is significant for several reasons.
- the liver extensively metabolizes fentanyl.
- an oral dosage form of fentanyl would tend to be less effective because the drug must be absorbed from the gastrointestinal tract and then delivered to the liver.
- Either an IV dose or an inhalation dose of fentanyl travels directly from its site of entry, a vein in the case of an IV or to the lung in the case of the present invention, to the brain, its primary site of action, before it passes through the liver.
- the administration of fentanyl to patients is currently provided in several dosage forms: intravenous, transdermal and transmucosal.
- the latter consists of a matrix of fentanyl citrate on a stick (Actiq® oral transmucosal fentanyl citrate).
- Actiq® oral transmucosal fentanyl citrate The product literature provided for Actiq indicate that 25% of the dose is absorbed from the buccal mucosa while the remaining 75% is swallowed with the saliva and is then slowly absorbed from the gastrointestinal tract. About 1 ⁇ 3 of this amount (25% of the total dose) escapes hepatic and intestinal first-pass elimination and becomes systemically available.
- a significant advantage of the delivery system of the present invention is that it provides a means for rapid absorption of drugs such as fentanyl into the blood system for delivery directly to the brain, without the use of needles or excipients and without being exposed to a first pass metabolism in the gastrointestinal tract or liver.
- D was the dose and AUC was the AUC determined to the last measurable time point.
- FIG. 26 plots the data obtained on the blood levels, by dog, for both the IV doses and the inhalation doses using device 1 as described above under Example 1.
- Table 2 summarizes the data collected from use of ADME device 1 for in vitro testing of fentanyl. Particle size was measured with a Moudi cascade impactor. TABLE 2 Compound Mass Mixing air volume (ug) (cc) MMAD (nm) GSD 20 400 71 1.9 25 400 72-78 1.7-1.8 50 400 77-88 1.7-185 100 400 100-105 1.4-1.8 200 400 103-123 1.6-1.9 300 400 140-160 1.8-2.1
- FIG. 27 compares the MAD calculated value for a GSD equal to 1.35 and 1.60 to actual data on MAD summarized in Table 2 for ADME device.
- MMAD Mass Mean Aerodynamic Diameter; the diameter of a particle of unit density material that exhibits the same aerodynamic behavior as the measured aerosol
- MMD Mass Mean Diameter; the diameter of a unit density particle
- the curves of FIG. 27 demonstrate a good correlation between the theoretical model based on the equations set forth earlier and actual data. Note that the theoretical prediction for small particles is less than the actual data. The reason, as stated earlier, is that when particle size becomes less than 80 nm the coagulation coefficient gets larger. As this happens a stable number concentration is reached at a lower number. If the calculation of MMD is redone with a number concentration of 0.5 ⁇ 10 9 /cc instead of 1.0 ⁇ 10 9/ cc, as used above, the curves shown in FIG. 28 result. As can be seen, the actual data fits the calculated data much better for the small particle sizes.
- ADME device 1 was slightly modified and the flow rate changed, as discussed below, to make a fine aerosol in the 1 to 3 micron particle size range.
- Airway section 140 was removed and the air channel heating/vaporization zone 70 was changed.
- An airway insert (not shown) had a “roof” that was 0.25 inches above the foil. There were no mixing rods as rapid mixing was not desirable in this example. Because of these two device changes, there was much less mixing with the air, thus the vapor/aerosol cloud was mixed with less air and produced a larger particle size aerosol.
- DOP dioctyl phthalate
- a fine particle size can be made with ADME device 1 merely by changing the ratio of the compound to the mixing air.
- device 300 the third embodiment of the present invention, is described in which a gas stream is passed into thin walled tube 302 having a coating 310 of compound 60 on the inside of the tube as shown in FIGS. 10 - 11 .
- the flow rate of the gas stream is controlled by valve 314 .
- This is another example that allows for rapid heat-up using resistive heating system 320 while controlling the flow direction of the vaporized compound.
- the carrier gas e.g., air, N2 and the like
- FIG. 12 shows an alternative heating system to resistive heating system 320 used in connection the third embodiment shown in FIGS. 10 - 11 .
- inductive heating system 350 consists of a plurality of ferrites 360 for conducting the magnetic flux to vaporize drug 310 .
- FIG. 13 shows the alternate to the third embodiment in which flow restrictor 370 is mounted within thin-walled tube 302 by means of support 374 within a housing (not shown) to increase the flow of mixing gas across the surface of a compound.
- device 400 the fourth embodiment of the present invention shown in FIGS. 14 - 15 , is described.
- a thin layer of compound 60 is deposited onto flat substrate 402 in a shape that has a high aspect ratio with the long direction of the deposition in the direction of airflow through airway tube 404 in housing 10 .
- Substrate 60 is held in a frame that is then mounted in a slide in the manner described in Example 1 above. The slide is able to travel within an airway along the direction of air travel.
- a motor (not shown) drives the slide.
- Heater 406 is positioned so that it can heat substrate 402 and thereby compound 60 . Heater 406 is connected to actuator 410 .
- Chamber 420 is filled with a gas and has outlet 430 connected to passageway 440 .
- Airflow is regulated through passageway 440 by valve 442 that is controlled by a controller (not shown).
- Passageway 440 is connected to nozzle 448 that is positioned above compound 60 deposited on substrate 402 .
- Chamber 440 has a means to compress the gas within it. In the embodiment, this is accomplished by the use of movable piston 450 driven by a motor (not shown). Alternatively, the chamber can be compressed by a lever articulated by the user.
- valve 442 Upon actuation of device 400 , valve 442 is opened, simultaneously with heater 406 being activated, and the slide and thereby compound 60 is moved under nozzle 448 . Gas from chamber 420 is directed onto the compound's surface as the compound is raised in temperature. Upon vaporization, compound 30 is free to move down airway tube 404 to the patient.
- device 500 the fifth embodiment of the present invention is described in which the problem of the presence of oxygen during the heat-up period is also solved.
- Compound 60 is placed in an inert atmosphere or under a vacuum in container 502 within housing 10 and is heated by resistance heater 504 upon being activated by actuator 508 as shown in FIG. 15. Once compound 60 has become vaporized it can then be ejected through outlet passage 510 into the air stream passing through tube 520 .
- FIG. 16 shows an alternative to the embodiment shown in FIG. 15 in which fan 530 re-circulates the inert atmosphere over the surface of compound 60 .
- the inert gas from a compressed gas cylinder (not shown) enters through inlet 540 and one-way valve 550 and exits through outlet passage 510 into tube 520 as in the above example.
- device 600 the sixth embodiment of the present invention is described in which compound 60 is deposited onto a substrate in the form of discrete particles 602 , e.g., aluminum oxide (alumina), silica, coated silica, carbon, graphite, diatomaceous earth, and other packing materials commonly used in gas chromatography.
- the coated particles are placed within first tube 604 sandwiched between filters 604 and 608 and are heated by resistance heater 610 upon being activated by actuator 620 as shown in FIG. 17.
- the resulting vapor from tube 604 is combined with the air or other gas passing through second tube 625 .
- FIG. 18 shows an alternative to the embodiment shown in FIG. 17 in which resistance heater 630 heats the air prior to passing through first tube 604 and over discrete particles 602 .
- the decomposition of the compound is primarily caused by the presence of oxygen and not heat, and if the partial pressure of the compound is sufficient to produce the vaporization necessary at a temperature that does not produce decomposition, then an additional method of vaporization is possible.
- compound 60 is deposited into chamber 710 and is heated by resistance heater 715 upon being activated by actuator 720 as shown in FIG. 19. Upon heating, some of compound 60 will vaporize and then become ejected from chamber 710 by moving an inert gas entering housing 10 through inert gas inlet 725 and valve 728 and passing across the surface of compound 60 . The mixture of inert gas and vaporized compound passes through passage 730 and is then mixed with a gas passing through tube 735 .
- a tank is partially filled with DOP and placed inside an oven (not shown) having an inlet and an outlet.
- DOP was used as the test compound.
- the tank was purged with helium prior to heating the tank and its contents to a temperature of 350° C.
- Helium was pumped through the tank and used to carry the DOP vapor out of the outlet.
- the gaseous mixture of helium and vaporized compound 60 was introduced into different size mixing tubes through a nozzle. Each of the tubes had air moving through them at 14 liters/minute. The nozzle was perpendicular to the flow direction. After this gaseous mixture was mixed with the air, the resulting aerosol was introduced into a parallel flow diffusion battery for particle size analysis. Results are set forth in Table 4 below. TABLE 4 Mixing tube size (ID) MMAD GSD 4.8 mm 65 nm 1.3 14 mm 516 nm 3.3
- progressive heating is used during which multiple sections of a substrate are heated sequentially.
- the compound is deposited uniformly on the substrate.
- a movable heating zone is used. Compared to the entire surface area that the compound is laid down on, a relatively small heating area is generated in this example and moved, or “swept out” over the compound deposition area. A number of specific means for accomplishing this are described below.
- a variety of heating methods can be used to heat the substrate upon which a compound has been deposited.
- a small zone in the substrate can be heated or only a segment of the substrate or portion of the compound can be directly heated.
- an inductive heater heating method was utilized, which heated a zone in the foil substrate. Regardless of the heating method, as long as only a small zone of the compound and/or the substrate is heated, it is possible to move the heater relative to the substrate/compound.
- an inductive heating zone was induced in a conductive substrate that was in direct contact with the compound. The substrate was moved relative to this magnetic field, causing the compound to be locally vaporized.
- Device 800 An alternative device for producing a moving heating zone was accomplished by device 800 , the eighth embodiment of the present invention as shown in FIG. 20.
- Device 800 is referred as the gradient heating device.
- thermally conductive substrate 802 was heated by resistance heater 810 at the upstream end of tube 820 , and the thermal energy was allowed to travel along substrate 802 . This produced, when observed in a particular location, a heat up rate that was determined from the characteristics of the thermally conductive substrate. By varying the material and its cross sectional area, it was possible to control the rate of heat up.
- the source of the thermal energy can originate from a variety of other heating methods.
- a simple resistive heater 810 is shown. This resistive heater was embedded in substrate 802 at one end. However, it could be embedded into both ends, or in a variety of positions along the substrate and still allow the temperature gradient to move along the carrier and/or substrate shown in FIG. 20.
- a 4-inch long piece of aluminum was fitted with a 150-watt cartridge heater at one end.
- the heater was powered with a variac AC power transformer.
- the thickness of the aluminum was designed to ensure that heat would transverse from one end of the aluminum to the other in approximately 30 seconds.
- an indentation was machined to hold the compound and to hold one of two top covers.
- the indentation for the compound was approximately 3.5 inches long and 0.4 inches wide.
- the indentation was 0.025 inches deep, and was filled with 1 mg of DOP.
- the first top consisted of a sheet of flat glass placed 0.04 inches above the heated surface, creating an airway. At the exit end an outlet was fitted allowing the air to be drawn into an analytical measurement device. Air was made to flow through the airway at a rate of 15 liters/minute.
- a third method established a set of heated zones, energized sequentially.
- the zones could be produced from any of the heating devices including a resistive heater as disclosed in Rosen, PCT Publication No. 94/09842, published May 11, 1994, the relevant portions of which are incorporated herein by reference.
- a substrate could have three (3) sections A, B, C. where section A is first heated until the compound have been vaporized followed by the section B, and then C.
- a fourth method involved heating a zone in a substrate with an inductive heater, and then by manipulating the magnetic field, causing the induced current in the substrate to move along the substrate. This was accomplished by a number of methods. One method was to use a ferrite with a saturation value such that, by increasing the electrical field internal to the ferrite, the resultant magnetic field leaves the confines of the ferrite and enters a different area of the substrate.
- Another method involved constructing a ferrite with a shape that can be changed, such as opening up an air gap, and thereby changing the shape of the magnetic field.
- An additional method involved incrementally heating a substrate through the focusing and/or de-focusing of all forms of photon energy, especially in the visible and IR spectrum.
- FIGS. 21 - 22 The ninth embodiment of the present invention is shown in FIGS. 21 - 22 as screen device 900 .
- device 900 air was channeled through a fine mesh metal screen 902 that had the drug deposited thereon. Rapid heating and/or rapid cooling, as stated above, can preclude decomposition.
- This example involves rapidly mixing a compound, once it has vaporized, into air.
- a thin (0.01 to 10 micron) layer of compound can be deposited onto fine mesh screen 902 , e.g., 200 and 400 mesh screens were used in this example.
- Screen 902 was positioned across airway passage 910 .
- airway passage 910 was constructed from 18 mm diameter glass tubing.
- the passage can be made in any shape with a comparable cross-sectional area and out of any suitable material.
- the screen size, mesh, and the amount of compound were chosen in this example so that a gas could pass through the screen without interference once the compound had been deposited on it.
- the two sides of the screen were electrically connected to charged capacitor 920 through silicon-controlled rectifier (SCR) 922 to make a circuit.
- SCR silicon-controlled rectifier
- the charge of the capacitor was calculated and set at a value such that, when actuator 930 closed SCR 922 , the energy from capacitor 920 was converted to a desired temperature rise in screen 902 .
- the discharge rate (the RC time constant) of the capacitor was rapid, and on the order of a few milliseconds, i.e. less than 20 milliseconds, preferably in the range of about 2 to about 10 milliseconds.
- the deposited compound was rapidly vaporized. Because air moved through screen 902 , the vaporized compound rapidly mixed with air and cooled.
- the compound was deposited onto the fine stainless steel screen, e.g., 200 mesh, made from 316 stainless steel, having measurements of 2.54 cm. ⁇ 2.54 cm.
- the current from the capacitor was passed between one edge and another. It was not necessary to heat the screen to temperatures comparable to the thin foil in Example 1, because the compound vaporized at a lower temperature due to the rapid air movement. Rapid air movement allowed the compound to vaporize at a lower vapor pressure, since airflow constantly removed compound vapors from the surface as soon as they were formed. Thus, the compound vaporized at a lower temperature without decomposition.
- Deposition of the compound onto the screen was accomplished by mixing the compound with an organic solvent until the compound dissolved. The resulting solution was then applied to the fine stainless steel screen 902 and the solvent was allowed to evaporate. The screen was then inserted into holder 940 that electrically connected two sides of screen 902 to the power circuit described above.
- a 10,000 mF capacitor was discharged while the gas was passing through screen 902 .
- the rapid heat up of the screen resulted in a rapid vaporization of the compound into the gas.
- the resulting vaporized compound was mixed into a small volume of the gas. Because the ratio of the mass of the compound to the volume of the mixing gas was large, a fine (1-3 micron diameter) particle aerosol was made.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nozzles (AREA)
- Organic Insulating Materials (AREA)
- Dental Preparations (AREA)
Priority Applications (66)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/057,198 US20030051728A1 (en) | 2001-06-05 | 2001-10-26 | Method and device for delivering a physiologically active compound |
US10/057,197 US7766013B2 (en) | 2001-06-05 | 2001-10-26 | Aerosol generating method and device |
AU2002311926A AU2002311926B2 (en) | 2001-06-05 | 2002-05-13 | Method of forming an aerosol for inhalation delivery |
CA002447210A CA2447210C (en) | 2001-06-05 | 2002-05-13 | Delivery of aerosols containing small particles through an inhalation route |
CA2646756A CA2646756C (en) | 2001-06-05 | 2002-05-13 | Method of forming an aerosol for inhalation delivery |
NZ529296A NZ529296A (en) | 2001-06-05 | 2002-05-13 | An aerosol forming device for use in inhalation therapy |
US10/146,080 US7942147B2 (en) | 2001-06-05 | 2002-05-13 | Aerosol forming device for use in inhalation therapy |
CA002447354A CA2447354C (en) | 2001-06-05 | 2002-05-13 | Method of forming an aerosol for inhalation delivery |
NZ529298A NZ529298A (en) | 2001-06-05 | 2002-05-13 | Method of forming an aerosol for use in inhalation therapy |
HU0401948A HUP0401948A3 (en) | 2001-06-05 | 2002-05-13 | Method of forming an aerosol for inhalation delivery |
MXPA03011269A MXPA03011269A (es) | 2001-06-05 | 2002-05-13 | Metodo para formar un aerosol para suministro de inhalacion. |
AU2002311923A AU2002311923B2 (en) | 2001-06-05 | 2002-05-13 | An aerosol forming device for use in inhalation therapy |
US10/146,088 US7537009B2 (en) | 2001-06-05 | 2002-05-13 | Method of forming an aerosol for inhalation delivery |
PCT/US2002/018608 WO2002098390A2 (en) | 2001-06-05 | 2002-05-13 | Delivery of aerosols containing small particles through an inhalation route |
HU0401008A HUP0401008A2 (en) | 2001-06-05 | 2002-05-13 | An aerosol forming device for use in inhalation therapy |
ES02739267T ES2343678T3 (es) | 2001-06-05 | 2002-05-13 | Procedimiento de formacion de un aerosol para su administracion por inhalacion. |
EP02739262A EP1392381B9 (de) | 2001-06-05 | 2002-05-13 | Zerstäubungsvorrichtung zur verwendung in der inhalationstherapie |
JP2003501430A JP2004532881A (ja) | 2001-06-05 | 2002-05-13 | 吸入経路を介す微粒子含有エアロゾルの送出 |
JP2003501533A JP4912566B2 (ja) | 2001-06-05 | 2002-05-13 | 吸入療法に使用するためのエアロゾル形成装置 |
EP02739267A EP1392242B1 (de) | 2001-06-05 | 2002-05-13 | Verfahren zur herstellung eines aerosols zur inhalation |
IL15895402A IL158954A0 (en) | 2001-06-05 | 2002-05-13 | Method of forming an aerosol for inhalation therapy |
CNB02811406XA CN1304067C (zh) | 2001-06-05 | 2002-05-13 | 用于吸入疗法的气溶胶的形成设备 |
IL15895502A IL158955A0 (en) | 2001-06-05 | 2002-05-13 | An aerosol forming device for use in inhalation therapy |
DE60236430T DE60236430D1 (en) | 2001-06-05 | 2002-05-13 | Ation |
EP02742015A EP1392263A2 (de) | 2001-06-05 | 2002-05-13 | Verabreichung von aerosolen, die kleine teilchen enthalten, durch inhalation |
PL02373836A PL373836A1 (en) | 2001-06-05 | 2002-05-13 | Method of forming an aerosol for inhalation delivery |
PL02374048A PL374048A1 (en) | 2001-06-05 | 2002-05-13 | An aerosol forming device for use in inhalation therapy |
DE60239604T DE60239604D1 (de) | 2001-06-05 | 2002-05-13 | Zerstäubungsvorrichtung zur verwendung in der inhalationstherapie |
CZ20033249A CZ20033249A3 (cs) | 2001-06-05 | 2002-05-13 | Způsob tvorby aerosolu pro inhalaci |
MXPA03011268A MXPA03011268A (es) | 2001-06-05 | 2002-05-13 | Dispositivo formador de aerosol para utilizarse en terapia de inhalacion. |
PCT/US2002/015363 WO2002098496A1 (en) | 2001-06-05 | 2002-05-13 | An aerosol forming device for use in inhalation therapy |
CNB028114078A CN100496458C (zh) | 2001-06-05 | 2002-05-13 | 用于吸入递送的气溶胶的形成方法 |
AT02739267T ATE468105T1 (de) | 2001-06-05 | 2002-05-13 | Verfahren zur herstellung eines aerosols zur inhalation |
JP2003501429A JP4510438B2 (ja) | 2001-06-05 | 2002-05-13 | 吸入療法に使用するためのエアロゾル形成方法 |
CA2447081A CA2447081C (en) | 2001-06-05 | 2002-05-13 | An aerosol forming device for use in inhalation therapy |
AT02739262T ATE503516T1 (de) | 2001-06-05 | 2002-05-13 | Zerstäubungsvorrichtung zur verwendung in der inhalationstherapie |
CZ20033223A CZ20033223A3 (cs) | 2001-06-05 | 2002-05-13 | Zařízení tvořící aerosol pro použití v inhalační terapii |
PCT/US2002/015425 WO2002098389A1 (en) | 2001-06-05 | 2002-05-13 | Method of forming an aerosol for inhalation delivery |
US10/146,515 US6682716B2 (en) | 2001-06-05 | 2002-05-13 | Delivery of aerosols containing small particles through an inhalation route |
US10/633,877 US7585493B2 (en) | 2001-05-24 | 2003-08-04 | Thin-film drug delivery article and method of use |
US10/633,876 US7645442B2 (en) | 2001-05-24 | 2003-08-04 | Rapid-heating drug delivery article and method of use |
US10/696,959 US20040096402A1 (en) | 2001-06-05 | 2003-10-30 | Delivery of aerosols containing small particles through an inhalation route |
US10/718,982 US7090830B2 (en) | 2001-05-24 | 2003-11-20 | Drug condensation aerosols and kits |
HK05100362A HK1068293A1 (en) | 2001-06-05 | 2005-01-14 | An aerosol forming device for use in inhalation therapy |
HK05100459.9A HK1068268A1 (en) | 2001-06-05 | 2005-01-18 | Method of forming an aerosol for inhalation delivery |
US11/504,419 US20070122353A1 (en) | 2001-05-24 | 2006-08-15 | Drug condensation aerosols and kits |
US11/687,466 US20080038363A1 (en) | 2001-05-24 | 2007-03-16 | Aerosol delivery system and uses thereof |
US11/744,799 US20070286816A1 (en) | 2001-05-24 | 2007-05-04 | Drug and excipient aerosol compositions |
AU2007207865A AU2007207865B2 (en) | 2001-06-05 | 2007-08-16 | An aerosol forming device for use in inhalation therapy |
AU2007231750A AU2007231750B2 (en) | 2001-06-05 | 2007-10-30 | Method of forming an aerosol for inhalation delivery |
US12/117,737 US8235037B2 (en) | 2001-05-24 | 2008-05-08 | Drug condensation aerosols and kits |
US12/471,070 US8074644B2 (en) | 2001-06-05 | 2009-05-22 | Method of forming an aerosol for inhalation delivery |
JP2009259070A JP2010057950A (ja) | 2001-06-05 | 2009-11-12 | 吸入療法に使用するためのエアロゾル形成装置 |
US12/847,584 US9308208B2 (en) | 2001-06-05 | 2010-07-30 | Aerosol generating method and device |
US13/078,600 US20110240022A1 (en) | 2001-06-05 | 2011-04-01 | Aerosol forming device for use in inhalation therapy |
US13/078,606 US20110240013A1 (en) | 2001-06-05 | 2011-04-01 | Method of forming an aerosol for inhalation delivery |
US13/078,516 US20110244020A1 (en) | 2001-05-24 | 2011-04-01 | Drug condensation aerosols and kits |
US13/569,006 US9211382B2 (en) | 2001-05-24 | 2012-08-07 | Drug condensation aerosols and kits |
US13/851,577 US8955512B2 (en) | 2001-06-05 | 2013-03-27 | Method of forming an aerosol for inhalation delivery |
US14/077,015 US9439907B2 (en) | 2001-06-05 | 2013-11-11 | Method of forming an aerosol for inhalation delivery |
US14/078,577 US9687487B2 (en) | 2001-06-05 | 2013-11-13 | Aerosol forming device for use in inhalation therapy |
US14/078,679 US9440034B2 (en) | 2001-05-24 | 2013-11-13 | Drug condensation aerosols and kits |
US14/624,311 US20150157635A1 (en) | 2001-06-05 | 2015-02-17 | Method Of Forming An Aerosol For Inhalation Delivery |
US15/262,954 US10350157B2 (en) | 2001-05-24 | 2016-09-12 | Drug condensation aerosols and kits |
US15/633,508 US11065400B2 (en) | 2001-06-05 | 2017-06-26 | Aerosol forming device for use in inhalation therapy |
US16/510,846 US20190336437A1 (en) | 2001-05-24 | 2019-07-12 | Drug Condensation Aerosols And Kits |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29622501P | 2001-06-05 | 2001-06-05 | |
US10/057,198 US20030051728A1 (en) | 2001-06-05 | 2001-10-26 | Method and device for delivering a physiologically active compound |
US10/057,197 US7766013B2 (en) | 2001-06-05 | 2001-10-26 | Aerosol generating method and device |
Related Parent Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/057,197 Continuation-In-Part US7766013B2 (en) | 2001-05-24 | 2001-10-26 | Aerosol generating method and device |
US10/057,197 Continuation US7766013B2 (en) | 2001-05-24 | 2001-10-26 | Aerosol generating method and device |
US10/146,080 Continuation-In-Part US7942147B2 (en) | 2001-05-24 | 2002-05-13 | Aerosol forming device for use in inhalation therapy |
US10/633,876 Continuation-In-Part US7645442B2 (en) | 2001-05-24 | 2003-08-04 | Rapid-heating drug delivery article and method of use |
Related Child Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/057,197 Continuation-In-Part US7766013B2 (en) | 2001-05-24 | 2001-10-26 | Aerosol generating method and device |
US10/146,088 Continuation-In-Part US7537009B2 (en) | 2001-05-24 | 2002-05-13 | Method of forming an aerosol for inhalation delivery |
US10/146,515 Continuation-In-Part US6682716B2 (en) | 2001-05-24 | 2002-05-13 | Delivery of aerosols containing small particles through an inhalation route |
US10/146,080 Continuation-In-Part US7942147B2 (en) | 2001-05-24 | 2002-05-13 | Aerosol forming device for use in inhalation therapy |
US10/633,876 Continuation-In-Part US7645442B2 (en) | 2001-05-24 | 2003-08-04 | Rapid-heating drug delivery article and method of use |
US10/633,877 Continuation-In-Part US7585493B2 (en) | 2001-05-24 | 2003-08-04 | Thin-film drug delivery article and method of use |
US10/718,982 Continuation-In-Part US7090830B2 (en) | 2001-05-24 | 2003-11-20 | Drug condensation aerosols and kits |
US11/687,466 Continuation-In-Part US20080038363A1 (en) | 2001-05-24 | 2007-03-16 | Aerosol delivery system and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030051728A1 true US20030051728A1 (en) | 2003-03-20 |
Family
ID=27369190
Family Applications (15)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/057,198 Abandoned US20030051728A1 (en) | 2001-05-24 | 2001-10-26 | Method and device for delivering a physiologically active compound |
US10/057,197 Expired - Fee Related US7766013B2 (en) | 2001-05-24 | 2001-10-26 | Aerosol generating method and device |
US10/146,088 Active 2024-10-28 US7537009B2 (en) | 2001-05-24 | 2002-05-13 | Method of forming an aerosol for inhalation delivery |
US10/146,080 Expired - Fee Related US7942147B2 (en) | 2001-05-24 | 2002-05-13 | Aerosol forming device for use in inhalation therapy |
US10/146,515 Expired - Fee Related US6682716B2 (en) | 2001-05-24 | 2002-05-13 | Delivery of aerosols containing small particles through an inhalation route |
US10/696,959 Abandoned US20040096402A1 (en) | 2001-06-05 | 2003-10-30 | Delivery of aerosols containing small particles through an inhalation route |
US12/471,070 Expired - Fee Related US8074644B2 (en) | 2001-06-05 | 2009-05-22 | Method of forming an aerosol for inhalation delivery |
US12/847,584 Expired - Fee Related US9308208B2 (en) | 2001-06-05 | 2010-07-30 | Aerosol generating method and device |
US13/078,600 Abandoned US20110240022A1 (en) | 2001-06-05 | 2011-04-01 | Aerosol forming device for use in inhalation therapy |
US13/078,606 Abandoned US20110240013A1 (en) | 2001-06-05 | 2011-04-01 | Method of forming an aerosol for inhalation delivery |
US13/851,577 Expired - Fee Related US8955512B2 (en) | 2001-06-05 | 2013-03-27 | Method of forming an aerosol for inhalation delivery |
US14/077,015 Expired - Lifetime US9439907B2 (en) | 2001-06-05 | 2013-11-11 | Method of forming an aerosol for inhalation delivery |
US14/078,577 Expired - Lifetime US9687487B2 (en) | 2001-06-05 | 2013-11-13 | Aerosol forming device for use in inhalation therapy |
US14/624,311 Abandoned US20150157635A1 (en) | 2001-06-05 | 2015-02-17 | Method Of Forming An Aerosol For Inhalation Delivery |
US15/633,508 Expired - Lifetime US11065400B2 (en) | 2001-06-05 | 2017-06-26 | Aerosol forming device for use in inhalation therapy |
Family Applications After (14)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/057,197 Expired - Fee Related US7766013B2 (en) | 2001-05-24 | 2001-10-26 | Aerosol generating method and device |
US10/146,088 Active 2024-10-28 US7537009B2 (en) | 2001-05-24 | 2002-05-13 | Method of forming an aerosol for inhalation delivery |
US10/146,080 Expired - Fee Related US7942147B2 (en) | 2001-05-24 | 2002-05-13 | Aerosol forming device for use in inhalation therapy |
US10/146,515 Expired - Fee Related US6682716B2 (en) | 2001-05-24 | 2002-05-13 | Delivery of aerosols containing small particles through an inhalation route |
US10/696,959 Abandoned US20040096402A1 (en) | 2001-06-05 | 2003-10-30 | Delivery of aerosols containing small particles through an inhalation route |
US12/471,070 Expired - Fee Related US8074644B2 (en) | 2001-06-05 | 2009-05-22 | Method of forming an aerosol for inhalation delivery |
US12/847,584 Expired - Fee Related US9308208B2 (en) | 2001-06-05 | 2010-07-30 | Aerosol generating method and device |
US13/078,600 Abandoned US20110240022A1 (en) | 2001-06-05 | 2011-04-01 | Aerosol forming device for use in inhalation therapy |
US13/078,606 Abandoned US20110240013A1 (en) | 2001-06-05 | 2011-04-01 | Method of forming an aerosol for inhalation delivery |
US13/851,577 Expired - Fee Related US8955512B2 (en) | 2001-06-05 | 2013-03-27 | Method of forming an aerosol for inhalation delivery |
US14/077,015 Expired - Lifetime US9439907B2 (en) | 2001-06-05 | 2013-11-11 | Method of forming an aerosol for inhalation delivery |
US14/078,577 Expired - Lifetime US9687487B2 (en) | 2001-06-05 | 2013-11-13 | Aerosol forming device for use in inhalation therapy |
US14/624,311 Abandoned US20150157635A1 (en) | 2001-06-05 | 2015-02-17 | Method Of Forming An Aerosol For Inhalation Delivery |
US15/633,508 Expired - Lifetime US11065400B2 (en) | 2001-06-05 | 2017-06-26 | Aerosol forming device for use in inhalation therapy |
Country Status (17)
Country | Link |
---|---|
US (15) | US20030051728A1 (de) |
EP (3) | EP1392263A2 (de) |
JP (4) | JP4510438B2 (de) |
CN (2) | CN100496458C (de) |
AT (2) | ATE468105T1 (de) |
AU (4) | AU2002311926B2 (de) |
CA (4) | CA2447081C (de) |
CZ (2) | CZ20033223A3 (de) |
DE (2) | DE60239604D1 (de) |
ES (1) | ES2343678T3 (de) |
HK (2) | HK1068293A1 (de) |
HU (2) | HUP0401008A2 (de) |
IL (2) | IL158955A0 (de) |
MX (2) | MXPA03011268A (de) |
NZ (2) | NZ529296A (de) |
PL (2) | PL374048A1 (de) |
WO (3) | WO2002098389A1 (de) |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030062042A1 (en) * | 2001-06-05 | 2003-04-03 | Wensley Martin J. | Aerosol generating method and device |
US20030209240A1 (en) * | 2002-05-13 | 2003-11-13 | Hale Ron L. | Method and apparatus for vaporizing a compound |
US20040009128A1 (en) * | 2002-05-13 | 2004-01-15 | Rabinowitz Joshua D | Delivery of drug amines through an inhalation route |
US20040102434A1 (en) * | 2002-11-26 | 2004-05-27 | Alexza Molecular Delivery Corporation | Method for treating pain with loxapine and amoxapine |
US20040105819A1 (en) * | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Respiratory drug condensation aerosols and methods of making and using them |
WO2004096118A2 (en) | 2003-04-29 | 2004-11-11 | Neurim Pharmaceuticals (1991) Ltd. | Composition for improving cognition and memory |
US20040234916A1 (en) * | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
US20050034723A1 (en) * | 2003-08-04 | 2005-02-17 | Bryson Bennett | Substrates for drug delivery device and methods of preparing and use |
WO2005053444A1 (de) * | 2003-12-05 | 2005-06-16 | Lts Lohmann Therapie-Systeme Ag | Inhalator für basische pharmazeutische wirkstoffe sowie verfahren für dessen herstellung |
US20060153779A1 (en) * | 2001-05-24 | 2006-07-13 | Alexza Pharmaceuticals, Inc. | Delivery of stimulants through an inhalation route |
US20060233718A1 (en) * | 2001-05-24 | 2006-10-19 | Alexza Pharmaceuticals, Inc. | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
US20060251810A1 (en) * | 2005-05-03 | 2006-11-09 | Eastman Kodak Company | Metering material to promote rapid vaporization |
US20060257328A1 (en) * | 2001-11-21 | 2006-11-16 | Alexza Pharmaceuticals, Inc. | Delivery of caffeine through an inhalation route |
US20070070612A1 (en) * | 2005-09-23 | 2007-03-29 | Bull, S.A.S. | System for maintaining an assembly of three parts in position that exerts a predetermined compressive force on the itermediate part |
US20070155255A1 (en) * | 2005-12-29 | 2007-07-05 | Charles Galauner | Heating element connector assembly with press-fit terminals |
US20080299048A1 (en) * | 2006-12-22 | 2008-12-04 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositions |
US20080311176A1 (en) * | 2001-05-24 | 2008-12-18 | Alexza Pharmaceuticals, Inc. | Drug Condensation Aerosols And Kits |
US20090062254A1 (en) * | 2002-11-26 | 2009-03-05 | Alexza Pharmaceuticals, Inc. | Acute Treatment of Headache with Phenothiazine Antipsychotics |
US7513781B2 (en) | 2006-12-27 | 2009-04-07 | Molex Incorporated | Heating element connector assembly with insert molded strips |
US20090107495A1 (en) * | 2005-07-21 | 2009-04-30 | National Institute For Materials Science | Device for inhalation of medicine |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US20100055048A1 (en) * | 2002-05-20 | 2010-03-04 | Alexza Pharmaceuticals, Inc. | Acute treatment of headache with phenothiazine antipsychotics |
US20100065052A1 (en) * | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Heating Units |
US20100068154A1 (en) * | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Printable Igniters |
US20100300433A1 (en) * | 2009-05-28 | 2010-12-02 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
US7923662B2 (en) | 2004-05-20 | 2011-04-12 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US7981401B2 (en) | 2002-11-26 | 2011-07-19 | Alexza Pharmaceuticals, Inc. | Diuretic aerosols and methods of making and using them |
US8333197B2 (en) | 2004-06-03 | 2012-12-18 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
WO2014085719A1 (en) * | 2012-11-28 | 2014-06-05 | E-Nicotine Technology, Inc. | Methods and devices for compound delivery |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
US9724341B2 (en) | 2013-07-11 | 2017-08-08 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid |
US10034988B2 (en) | 2012-11-28 | 2018-07-31 | Fontem Holdings I B.V. | Methods and devices for compound delivery |
US10194693B2 (en) | 2013-09-20 | 2019-02-05 | Fontem Holdings 1 B.V. | Aerosol generating device |
US10506830B2 (en) | 2017-09-22 | 2019-12-17 | Altria Client Services Llc | Air flow design for an e-vaping cartridge, method of making the e-vaping cartridge, and e-vaping device including the cartridge |
US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
WO2020060992A1 (en) * | 2018-09-20 | 2020-03-26 | General Electric Company | Systems and methods for an inductively heated anesthetic vaporizer |
US10625033B2 (en) | 2007-03-09 | 2020-04-21 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US10786635B2 (en) | 2010-08-26 | 2020-09-29 | Alexza Pharmaceuticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
EP3313213B1 (de) | 2015-06-29 | 2021-03-10 | Nicoventures Trading Limited | Elektronisches aerosolbereitstellungssystem |
EP3646669B1 (de) | 2017-06-30 | 2021-07-28 | Philip Morris Products S.A. | Aerosolerzeugungsvorrichtung und aerosolerzeugungssystem mit induktionsheizsystem mit effizienter leistungsregelung |
US11241383B2 (en) | 2016-12-09 | 2022-02-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
US11511054B2 (en) | 2015-03-11 | 2022-11-29 | Alexza Pharmaceuticals, Inc. | Use of antistatic materials in the airway for thermal aerosol condensation process |
US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
US20230414314A1 (en) * | 2017-10-02 | 2023-12-28 | Lightlab Imaging, Inc. | Intravascular Data Collection Probes And Related Assemblies |
US12036074B2 (en) | 2022-05-23 | 2024-07-16 | Lightlab Imaging, Inc. | Intravascular data collection probes and related assemblies |
Families Citing this family (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962904B1 (en) * | 1998-03-13 | 2005-11-08 | Connective Tissue Imagineering | Elastin peptide analogs and uses thereof |
US7090830B2 (en) * | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
WO2002094242A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
GB2381450B (en) * | 2001-10-31 | 2006-05-31 | Gw Pharma Ltd | Compositions for administration of natural or synthetic cannabinoids by vaporisation |
WO2003041693A1 (en) | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
WO2003072016A2 (en) * | 2001-11-19 | 2003-09-04 | Becton, Dickinson And Company | Pharmaceutical compositions in particulate form |
GB2384184B (en) * | 2002-01-10 | 2005-01-12 | Aea Technology Plc | Cannabis aerosol |
US7501113B2 (en) * | 2003-02-04 | 2009-03-10 | Philip Morris Usa Inc. | Aerosol formulations and aerosol delivery of buprenorphine |
US7648981B2 (en) * | 2003-02-28 | 2010-01-19 | Ym Biosciences Inc. | Opioid delivery system |
KR20070011344A (ko) * | 2003-02-28 | 2007-01-24 | 데렉스 쎄라퓨틱스 인코포레이티드 | 오피오이드 전달 시스템 |
US7648982B2 (en) * | 2003-02-28 | 2010-01-19 | Ym Biosciences Inc. | Opioid delivery system |
WO2004075879A1 (en) * | 2003-02-28 | 2004-09-10 | Delex Therapeutics Inc. | Opioid delivery system |
CN100381083C (zh) | 2003-04-29 | 2008-04-16 | 韩力 | 一种非可燃性电子喷雾香烟 |
US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
WO2005014090A1 (en) * | 2003-08-04 | 2005-02-17 | Alexza Pharmaceuticals, Inc. | Methods of determining film thicknesses for an aerosol delivery article |
US7252050B2 (en) * | 2003-09-04 | 2007-08-07 | Maury Dean Cole | Substance inhalation system |
WO2005037949A2 (en) * | 2003-10-07 | 2005-04-28 | Chrysalis Technologies Incorporated | Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine |
CN2719043Y (zh) | 2004-04-14 | 2005-08-24 | 韩力 | 雾化电子烟 |
CA2567840C (en) * | 2004-06-03 | 2014-08-19 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US20100006092A1 (en) * | 2004-08-12 | 2010-01-14 | Alexza Pharmaceuticals, Inc. | Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages |
US8628796B2 (en) * | 2004-12-09 | 2014-01-14 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
FR2880279A1 (fr) * | 2005-01-05 | 2006-07-07 | Cvb Sarl Sarl | Dispositif de diffusion multi-odeurs |
BRPI0608209A2 (pt) * | 2005-02-23 | 2010-11-09 | Teva Pharma | mistura de partìculas, composição sólida, método para tratamento de um paciente com mal de parkinson, processo para preparação de uma composição, e, composição farmacêutica sólida |
JP5087539B2 (ja) | 2005-05-18 | 2012-12-05 | ネクター セラピューティックス | 気管支内治療のためのバルブ、デバイス、および方法 |
EP1733753A1 (de) * | 2005-06-14 | 2006-12-20 | RIZK, Nelly Kamel | Vorrichtung zum Auftragen einer Zusammensetzung |
NZ561375A (en) | 2005-06-27 | 2011-06-30 | Biovail Lab Int Srl | Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound |
CA2617989C (en) * | 2005-08-23 | 2015-11-10 | Aerogen, Inc. | Self-sealing t-piece and valved t-piece |
WO2008048234A2 (en) * | 2005-08-26 | 2008-04-24 | North Carolina State University | Inhaler system for targeted maximum drug-aerosol delivery |
JP2009507925A (ja) * | 2005-09-13 | 2009-02-26 | エラン ファーマ インターナショナル リミテッド | ナノ粒子タダラフィル製剤 |
US8202535B2 (en) * | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US8357114B2 (en) * | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US9289583B2 (en) * | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US20070260491A1 (en) * | 2006-05-08 | 2007-11-08 | Pamela Palmer | System for delivery and monitoring of administration of controlled substances |
US20070286818A1 (en) * | 2006-06-07 | 2007-12-13 | Wyeth | Treating cystic fibrosis with antibiotics via an aerosol drug |
PE20080329A1 (es) * | 2006-06-07 | 2008-04-09 | Wyeth Corp | Tratamiento de fibrosis cistica con antibioticos por via de una droga en aerosol |
PT2032266E (pt) * | 2006-06-09 | 2013-03-25 | Philip Morris Prod | Gerador capilar de aerossóis aquecido indirectamente |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
EP2046290A4 (de) * | 2006-08-04 | 2011-08-17 | Insys Therapeutics Inc | Wässrige dronabinolformulierungen |
US20090054333A1 (en) * | 2006-10-17 | 2009-02-26 | Antonio Giordano | Peptide inhibitors of cyclin-dependent kinase activity and uses thereof |
WO2008073757A1 (en) * | 2006-12-07 | 2008-06-19 | Helsinn Healthcare Sa | Crystalline and amorphous forms of palonosetron hydrochloride |
EP1964564A1 (de) * | 2007-04-19 | 2008-09-03 | LAB International SRL | Durchbruchsschmerzbehandlung |
JP2010535774A (ja) * | 2007-08-06 | 2010-11-25 | インシス セラピューティクス インコーポレイテッド | 経口カンナビノイド液体製剤および治療方法 |
KR101606944B1 (ko) * | 2007-08-07 | 2016-03-28 | 아셀알엑스 파마슈티컬스 인코퍼레이티드 | 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법 |
AU2008310734B2 (en) | 2007-10-10 | 2014-06-05 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
EP2230934B8 (de) | 2007-12-14 | 2012-10-24 | AeroDesigns, Inc | Abgabe von aerosol-sprühbaren nahrungsmittelprodukten |
BRPI0908565A2 (pt) | 2008-03-06 | 2017-05-23 | Anacor Pharmaceuticals Inc | composto, formulação farmacêutica, métodos para reduzir a liberação de uma citocina ou de uma quimiocina, para tratar uma condição em um animal e para inibir uma fosfodiesterase |
NZ589742A (en) * | 2008-05-27 | 2012-06-29 | Univ Melbourne | Methods of treating mammals with eustachian tube dysfunctions with betahistine |
WO2010033207A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
US20110171312A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
US8945592B2 (en) * | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
EP2370136A4 (de) * | 2008-12-01 | 2015-12-30 | Map Pharmaceuticals Inc | Inhalative freisetzungsverfahren und vorrichtungen |
WO2010074753A1 (en) * | 2008-12-23 | 2010-07-01 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
WO2010107761A1 (en) | 2009-03-18 | 2010-09-23 | Acelrx Pharmaceuticals, Inc. | Improved storage and dispensing devices for administration of oral transmucosal dosage forms |
CN201445686U (zh) * | 2009-06-19 | 2010-05-05 | 李文博 | 高频感应雾化装置 |
US8488952B2 (en) * | 2009-06-22 | 2013-07-16 | Magic-Flight General Manufacturing, Inc. | Aromatic vaporizer |
US9180263B2 (en) * | 2009-07-01 | 2015-11-10 | Microdose Therapeutx, Inc. | Laboratory animal pulmonary dosing device |
PT2453864T (pt) * | 2009-07-17 | 2016-12-22 | Nektar Therapeutics | Sistemas e métodos para acionamento de nebulizadores selados |
US9149605B2 (en) | 2009-07-28 | 2015-10-06 | Clement Kleinstreuer | Methods and devices for targeted injection of microspheres |
AU2010308089B2 (en) | 2009-10-13 | 2015-05-21 | Philip Morris Products S.A. | Air freshening device |
US20110091544A1 (en) * | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
WO2011112531A2 (en) | 2010-03-08 | 2011-09-15 | Stc. Unm | Dry powder nebulizer |
CN102009012B (zh) * | 2010-03-31 | 2012-10-24 | 范维林 | 带温度控制的液态雾化气溶胶发生装置 |
US11247003B2 (en) | 2010-08-23 | 2022-02-15 | Darren Rubin | Systems and methods of aerosol delivery with airflow regulation |
MX338209B (es) | 2010-09-07 | 2016-04-07 | Anacor Pharmaceuticals Inc | Derivados de benzoxaborol para tratar infecciones bacterianas. |
US9775379B2 (en) | 2010-12-22 | 2017-10-03 | Syqe Medical Ltd. | Method and system for drug delivery |
WO2012170677A1 (en) | 2011-06-07 | 2012-12-13 | Parion Sciences, Inc. | Methods of treatment |
US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
MY162480A (en) * | 2011-08-19 | 2017-06-15 | Japan Tobacco Inc | Aerosol Inhalator |
KR102060691B1 (ko) | 2011-09-06 | 2020-02-11 | 브리티시 아메리칸 토바코 (인베스트먼츠) 리미티드 | 가열식 흡연가능 재료 |
US9854839B2 (en) | 2012-01-31 | 2018-01-02 | Altria Client Services Llc | Electronic vaping device and method |
KR101903028B1 (ko) * | 2012-03-09 | 2018-10-02 | 벡투라 게엠베하 | 흡입 장치용 혼합 채널 및 흡입 장치 |
WO2013138910A1 (en) | 2012-03-19 | 2013-09-26 | Michael Klein | Virtual respiratory gas delivery systems and circuits |
GB201217067D0 (en) | 2012-09-25 | 2012-11-07 | British American Tobacco Co | Heating smokable material |
US9403755B2 (en) * | 2013-01-18 | 2016-08-02 | Tonix Pharma Holdings Limited (Bermuda) | Isometheptene isomer |
CA3059172C (en) | 2013-03-15 | 2023-01-24 | Trudell Medical International | Ventilator circuit, adapter for use in ventilator circuit and methods for the use thereof |
GB2515992A (en) | 2013-03-22 | 2015-01-14 | British American Tobacco Co | Heating smokeable material |
CA3208137A1 (en) | 2013-05-06 | 2014-11-13 | Juul Labs, Inc. | Nicotine salt formulations for aerosol devices and methods thereof |
WO2014190079A2 (en) | 2013-05-22 | 2014-11-27 | Njoy, Inc. | Compositions, devices, and methods for nicotine aerosol delivery |
WO2016004409A1 (en) * | 2014-07-03 | 2016-01-07 | Luxena Pharmaceuticals, Inc. | Novel aerosol formulations of ondansetron and uses thereof |
CN104274426A (zh) | 2013-07-03 | 2015-01-14 | 陆克塞纳医药公司 | 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途 |
US10010692B2 (en) * | 2013-07-08 | 2018-07-03 | Virginia Commonwealth University | Systems, devices, and methods for changing therapeutic aerosol size and improving efficiency of ventilation and aerosol drug delivery |
US11471618B2 (en) | 2014-11-09 | 2022-10-18 | Sipnose Ltd. | Adjustable dosing delivery and multi sectioned drug compartment |
US11116914B2 (en) | 2014-11-09 | 2021-09-14 | Sipnose Ltd. | Device and method for aerosolized delivering of substance to a natural orifice of the body |
US11992604B2 (en) | 2014-11-09 | 2024-05-28 | Sipnose Ltd. | Devices and methods for delivering a substance to a body cavity |
DE202013105715U1 (de) | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers |
US11278682B2 (en) | 2014-11-09 | 2022-03-22 | Sipnose Ltd. | Device and method for aerosolized delivery of substance to a natural orifice of the body |
US10980273B2 (en) | 2013-11-12 | 2021-04-20 | VMR Products, LLC | Vaporizer, charger and methods of use |
US10039321B2 (en) | 2013-11-12 | 2018-08-07 | Vmr Products Llc | Vaporizer |
US9781953B2 (en) | 2013-11-15 | 2017-10-10 | Vmr Products Llc | Vaporizer with cover sleeve |
EP3076805A4 (de) | 2013-12-05 | 2017-10-11 | PAX Labs, Inc. | Flüssige nikotinformulierungen für aerosolvorrichtungen und verfahren dafür |
EP3082428A4 (de) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5-inhibitorpulverformulierungen und zugehörige verfahren |
CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
CN104740737A (zh) * | 2013-12-26 | 2015-07-01 | 北京谊安医疗***股份有限公司 | 麻醉机及用于麻醉机的吸收回路的加热装置 |
HUE051726T2 (hu) | 2014-02-10 | 2021-03-29 | Philip Morris Products Sa | Fluidum-áteresztõ melegítõ részegységgel rendelkezõ aeroszol-fejlesztõ rendszer |
US10821240B2 (en) | 2014-02-11 | 2020-11-03 | Vapor Cartridge Technology Llc | Methods and drug delivery devices using cannabis |
US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
US9380813B2 (en) * | 2014-02-11 | 2016-07-05 | Timothy McCullough | Drug delivery system and method |
USD763502S1 (en) | 2014-03-04 | 2016-08-09 | Vmr Products Llc | Cartomizer for a vaporizer |
USD788697S1 (en) | 2014-03-04 | 2017-06-06 | VMR Products, LLC | Battery portion for a vaporizer |
USD752278S1 (en) | 2014-03-07 | 2016-03-22 | VMR Products, LLC | Battery portion of a vaporizer |
USD752280S1 (en) | 2014-03-07 | 2016-03-22 | VMR Products, LLC | Cartomizer for a vaporizer |
USD749505S1 (en) | 2014-03-07 | 2016-02-16 | VMR Products, LLC | Charger for a vaporizer |
TWI589308B (zh) * | 2014-03-25 | 2017-07-01 | 林信湧 | 一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法 |
USD804090S1 (en) | 2014-04-08 | 2017-11-28 | VMR Products, LLC | Vaporizer with indicators |
USD750320S1 (en) | 2014-08-05 | 2016-02-23 | VMR Products, LLC | Vaporizer |
TWI661782B (zh) | 2014-05-21 | 2019-06-11 | 瑞士商菲利浦莫里斯製品股份有限公司 | 電熱式氣溶膠產生系統、電熱式氣溶膠產生裝置及產生氣溶膠之方法 |
TWI669072B (zh) | 2014-05-21 | 2019-08-21 | 瑞士商菲利浦莫里斯製品股份有限公司 | 電熱式霧劑產生系統及用於此系統中之匣筒 |
MY175716A (en) * | 2014-05-21 | 2020-07-07 | Philip Morris Products Sa | Aerosol-generating article with multi-material susceptor |
GB201410562D0 (en) | 2014-06-13 | 2014-07-30 | Nicoventures Holdings Ltd | Aerosol provision system |
CA2952934A1 (en) | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
US11298477B2 (en) | 2014-06-30 | 2022-04-12 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
EP3160552B1 (de) | 2014-06-30 | 2019-05-08 | Syqe Medical Ltd. | Arzneimitteldosiskartusche für einen inhalator |
ES2904293T3 (es) | 2014-06-30 | 2022-04-04 | Syqe Medical Ltd | Dispositivo para vaporización e inhalación de sustancias aisladas |
EP3160565B1 (de) | 2014-06-30 | 2021-08-18 | Syqe Medical Ltd. | Vorrichtungen und systeme zur pulmonalen abgabe von wirkstoffen |
KR102482733B1 (ko) * | 2014-06-30 | 2022-12-29 | 사이키 메디컬 엘티디. | 유동 조절 흡입기 디바이스 |
AU2015283590B2 (en) | 2014-06-30 | 2020-04-16 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
CN104122179B (zh) * | 2014-08-05 | 2017-03-22 | 云南中烟工业有限责任公司 | 一种评价电子烟烟雾量的方法 |
MY197594A (en) | 2014-10-15 | 2023-06-27 | Altria Client Services Llc | Electronic vaping device and components thereof |
MX2017008428A (es) | 2014-12-23 | 2018-03-23 | Acelrx Pharmaceuticals Inc | Sistemas, dispositivos y métodos para dispensar formas de dosificación transmucosa oral. |
GB201423317D0 (en) | 2014-12-29 | 2015-02-11 | British American Tobacco Co | Apparatus for heating smokable material |
GB201423312D0 (en) | 2014-12-29 | 2015-02-11 | British American Tobacco Co | Heating device for apparatus for heating smokable material and method of manufacture |
GB201423318D0 (en) | 2014-12-29 | 2015-02-11 | British American Tobacco Co | Cartridge for use with apparatus for heating smokable material |
CN107438373A (zh) * | 2015-02-02 | 2017-12-05 | 无畏品牌责任有限公司 | 个人电子蒸发器 |
WO2016138505A1 (en) * | 2015-02-27 | 2016-09-01 | Ebbu, LLC | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
WO2017100369A1 (en) * | 2015-12-07 | 2017-06-15 | Ebbu, LLC | Printable cannabinoid and terpene compositions |
GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
US9943388B2 (en) | 2015-06-30 | 2018-04-17 | Maury D. Cole | Substance inhalation system and method |
US10994084B2 (en) | 2015-06-30 | 2021-05-04 | Maury D. Cole | Substance inhalation system and method |
CA2991108A1 (en) | 2015-07-02 | 2017-01-05 | Civitas Therapeutics, Inc. | Triptan powders for pulmonary delivery |
US20170038184A1 (en) * | 2015-08-06 | 2017-02-09 | Charles E. Ankner | Formulation delivery system |
US20170055575A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Material for use with apparatus for heating smokable material |
US20170055574A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Cartridge for use with apparatus for heating smokable material |
US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
US20170119050A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Article for Use with Apparatus for Heating Smokable Material |
US20170119051A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Article for Use with Apparatus for Heating Smokable Material |
US20170119047A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Article for Use with Apparatus for Heating Smokable Material |
US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
ES2874087T3 (es) * | 2016-01-06 | 2021-11-04 | Syqe Medical Ltd | Tratamiento terapéutico con dosis bajas |
CN114712642A (zh) * | 2016-01-11 | 2022-07-08 | Syqe医药有限公司 | 个人用蒸发装置 |
US11027086B2 (en) * | 2016-02-07 | 2021-06-08 | The Government Of The United States As Represented By The Secretary Of The Army | Oro-nasal inhalation plethysmography mask exposure system |
WO2017153827A1 (en) | 2016-03-07 | 2017-09-14 | Wallbrooke Investments Ltd. | Inductive heating apparatus and related method |
US10244795B2 (en) * | 2016-03-31 | 2019-04-02 | Altria Client Services Llc | Vaporizing assembly comprising sheet heating element and liquid delivery device for an aerosol generating system |
EP3436117B1 (de) * | 2016-03-31 | 2021-09-22 | Philip Morris Products S.A. | Verdampfungsanordnung mit blattheizelement |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
CN109414178B (zh) * | 2016-05-03 | 2022-05-31 | 精呼吸股份有限公司 | 用于肺部健康管理的***和方法 |
CA3022840A1 (en) | 2016-05-05 | 2017-11-09 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
KR102468749B1 (ko) | 2016-06-29 | 2022-11-17 | 니코벤처스 트레이딩 리미티드 | 흡연가능 물질을 가열하기 위한 장치 |
CA3034004C (en) | 2016-08-29 | 2021-08-03 | Canopy Growth Corporation | Water soluble compositions comprising purified cannabinoids |
US10736359B2 (en) | 2016-12-02 | 2020-08-11 | VMR Products, LLC | Cartridge-based vaporizers |
US10231961B1 (en) | 2017-02-07 | 2019-03-19 | Genus Lifesciences Inc. | Pharmaceutical compositions and methods of using the same |
US10149843B1 (en) | 2017-02-07 | 2018-12-11 | Gneus Lifescineces Inc. | Pharmaceutical compositions and methods of using the same |
US10413505B1 (en) | 2017-02-07 | 2019-09-17 | Genus Lifesciences Inc. | Pharmaceutical compositions and methods of using the same |
SG11201908420WA (en) | 2017-03-13 | 2019-10-30 | Beyondspring Pharmaceuticals Inc | Compositions of plinabulin and use thereof |
US11529476B2 (en) | 2017-05-19 | 2022-12-20 | Pneuma Respiratory, Inc. | Dry powder delivery device and methods of use |
US10292436B2 (en) | 2017-07-10 | 2019-05-21 | Arc Innovations, Inc. | Electronic smoking systems, devices, and methods |
JP7048727B2 (ja) | 2017-09-15 | 2022-04-05 | ニコベンチャーズ トレーディング リミテッド | 喫煙材を加熱するための装置 |
JP2020536614A (ja) | 2017-10-04 | 2020-12-17 | ニューマ・リスパイラトリー・インコーポレイテッド | 呼吸により電気的に作動するインライン液滴送達装置および使用方法 |
US11771852B2 (en) | 2017-11-08 | 2023-10-03 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use |
JP2021511893A (ja) * | 2018-02-02 | 2021-05-13 | アレクザ・ファーマシューティカルズ・インコーポレイテッドAlexza Pharmaceuticals, Inc. | 電気式凝縮エアロゾル装置 |
CN112912124A (zh) * | 2018-05-17 | 2021-06-04 | 赛诺丝有限公司 | 用于向身体的自然腔道雾化递送物质的装置和方法 |
US11383049B2 (en) | 2018-11-05 | 2022-07-12 | Juul Labs, Inc. | Cartridges for vaporizer devices |
CN113163857A (zh) | 2018-11-05 | 2021-07-23 | 尤尔实验室有限公司 | 用于蒸发器装置的料筒 |
WO2020127225A1 (en) | 2018-12-17 | 2020-06-25 | Philip Morris Products S.A. | 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof |
CN113873903A (zh) * | 2019-01-07 | 2021-12-31 | 弗里茨·施密特 | 用于定性和/或定量地检测***植物中所含物质的方法及其中使用的套件 |
EP3927337B8 (de) | 2019-02-22 | 2024-03-20 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) zur behandlung von schweren depression |
CN109876252A (zh) * | 2019-04-04 | 2019-06-14 | 林晓霞 | 一种固定式小儿内科用雾化吸入装置 |
WO2021055079A1 (en) * | 2019-09-16 | 2021-03-25 | Vapor Cartridge Technology Llc | Drug delivery system with stackable substrates |
EP3868364A1 (de) | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol enthaltend 5-methoxy-n,n-dimethyltryptamine |
US11666553B2 (en) | 2020-02-25 | 2023-06-06 | North Cell Pharmceticals Inc. | Method of reducing anxiety in non-human mammals by increasing brain serotonin levels |
EP4277611A1 (de) | 2021-01-15 | 2023-11-22 | Aquestive Therapeutics, Inc. | Prodrug-zusammensetzungen und behandlungsverfahren |
EP4359046A1 (de) | 2021-06-22 | 2024-05-01 | Pneuma Respiratory, Inc. | Tröpfchenabgabevorrichtung mit schubausstoss |
RU209490U1 (ru) * | 2021-07-05 | 2022-03-16 | Общество с ограниченной ответственностью "ИнертГаз Медикал" | Универсальный ингаляционный аппарат для проведения терапии инертными газами с функцией подогрева газовой смеси |
EP4159192A1 (de) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Nasenspray auf dimethyltriptaminbasis für die personalisierte behandlung von neurologischen und psychiatrischen störungen |
CN114028595B (zh) * | 2021-10-28 | 2023-09-19 | 武汉生物制品研究所有限责任公司 | 一种新型冠状病毒气溶胶暴露***消毒及评价方法 |
CN113876748A (zh) * | 2021-11-22 | 2022-01-04 | 兆科药业(广州)有限公司 | 一种用于治疗肺动脉高压的曲前列尼尔气溶胶吸入剂的雾化方法 |
WO2023186835A1 (en) | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | Treatment of mental disorders |
Citations (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1535486A (en) * | 1922-08-28 | 1925-04-28 | James W Lundy | Electric-lamp bulb |
US1803334A (en) * | 1931-05-05 | Ootthujp lehmann | ||
US1864980A (en) * | 1932-06-28 | Vapobizeb | ||
US2243669A (en) * | 1941-05-27 | Electrical vaporizer | ||
US2309846A (en) * | 1941-03-06 | 1943-02-02 | Holm Einar Marius | Inhaler |
US2469656A (en) * | 1946-04-19 | 1949-05-10 | Peter H Lienert | Vaporizer |
US2887106A (en) * | 1956-09-27 | 1959-05-19 | Robinson Joseph | Combined vaporizer and cover for medicament jar |
US3080624A (en) * | 1963-03-12 | weber iii | ||
US3164600A (en) * | 1961-10-10 | 1965-01-05 | Res Lab Dr C Janssen N V | 1-aralkyl-4-(n-aryl-carbonyl amino)-piperidines and related compounds |
US3169095A (en) * | 1962-10-30 | 1965-02-09 | Rexall Drug Chemical | Self-propelling powder-dispensing compositions |
US3433791A (en) * | 1960-09-05 | 1969-03-18 | Reckitt & Sons Ltd | Endoethano nor oripavines and nor thebaines |
US3560607A (en) * | 1962-11-30 | 1971-02-02 | Fisons Pharmaceuticals Ltd | Aerosol formulations of finely divided solid medicaments with anionic surface-active agents |
US3930796A (en) * | 1973-09-13 | 1976-01-06 | Universal Oil Products Company | Catalytic fume control device |
US3949743A (en) * | 1973-03-19 | 1976-04-13 | Schick Incorporated | Medicated vapor production method and apparatus |
US4020379A (en) * | 1975-10-02 | 1977-04-26 | Eg&G, Inc. | Bulb-shaped flashtube with metal envelope |
US4183912A (en) * | 1978-01-16 | 1980-01-15 | American Home Products Corporation | Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine |
US4184099A (en) * | 1977-04-27 | 1980-01-15 | International Flavors & Fragrances Inc. | Composition for slow release of volatile ingredients at _high temperature; and article comprising same |
US4276243A (en) * | 1978-12-08 | 1981-06-30 | Western Electric Company, Inc. | Vapor delivery control system and method |
US4588721A (en) * | 1983-09-12 | 1986-05-13 | The Upjohn Company | Treatment of negative symptoms of schizophrenia |
US4647433A (en) * | 1984-10-01 | 1987-03-03 | Donald Spector | Long-life aroma-generating capsule |
US4647428A (en) * | 1984-06-04 | 1987-03-03 | Gyulay Joseph M | Air freshener method |
US4722334A (en) * | 1985-07-16 | 1988-02-02 | Transpirator Technologies, Inc. | Method and apparatus for pulmonary and cardiovascular conditioning of racehorses and competition animals |
US4735358A (en) * | 1986-03-04 | 1988-04-05 | Daiken Iko Kabushiki Kaisha | Method and apparatus of vaporizing active substances |
US4892109A (en) * | 1989-03-08 | 1990-01-09 | Brown & Williamson Tobacco Corporation | Simulated smoking article |
US4911157A (en) * | 1988-01-07 | 1990-03-27 | Pegasus Research Corporation | Self-regulating, heated nebulizer system |
US4924883A (en) * | 1987-03-06 | 1990-05-15 | R. J. Reynolds Tobacco Company | Smoking article |
US4935624A (en) * | 1987-09-30 | 1990-06-19 | Cornell Research Foundation, Inc. | Thermal-assisted electrospray interface (TAESI) for LC/MS |
US4984158A (en) * | 1988-10-14 | 1991-01-08 | Hillsman Dean | Metered dose inhaler biofeedback training and evaluation system |
US5017575A (en) * | 1987-06-09 | 1991-05-21 | Golwyn Daniel H | Treatment of immunologically based disorders, specifically Crohn's disease |
US5093894A (en) * | 1989-12-01 | 1992-03-03 | Philip Morris Incorporated | Electrically-powered linear heating element |
US5095921A (en) * | 1990-11-19 | 1992-03-17 | Philip Morris Incorporated | Flavor generating article |
US5109180A (en) * | 1989-12-14 | 1992-04-28 | Phillips Petroleum Company | Apparatus providing a shatter-resistant electric lamp |
US5112598A (en) * | 1988-05-04 | 1992-05-12 | Hermes Fabrik Pharmazeutischer Preparate Franz Gradinger Gmbh & Co. Kg | Vitamin a aerosol-inhalate preparations |
US5126123A (en) * | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
US5179966A (en) * | 1990-11-19 | 1993-01-19 | Philip Morris Incorporated | Flavor generating article |
US5186164A (en) * | 1991-03-15 | 1993-02-16 | Puthalath Raghuprasad | Mist inhaler |
US5285798A (en) * | 1991-06-28 | 1994-02-15 | R. J. Reynolds Tobacco Company | Tobacco smoking article with electrochemical heat source |
US5322075A (en) * | 1992-09-10 | 1994-06-21 | Philip Morris Incorporated | Heater for an electric flavor-generating article |
US5402517A (en) * | 1991-05-01 | 1995-03-28 | Reckitt & Colman Products Limited | Apparatus for emitting a volatile chemical agent by heating and means for adjusting a spacing between a heater and the chemical agent to regulate the rate of vaporization |
US5400969A (en) * | 1993-09-20 | 1995-03-28 | Keene; Christopher M. | Liquid vaporizer and diffuser |
US5408574A (en) * | 1989-12-01 | 1995-04-18 | Philip Morris Incorporated | Flat ceramic heater having discrete heating zones |
US5479948A (en) * | 1993-08-10 | 1996-01-02 | Philip Morris Incorporated | Electrical smoking article having continuous tobacco flavor web and flavor cassette therefor |
US5505214A (en) * | 1991-03-11 | 1996-04-09 | Philip Morris Incorporated | Electrical smoking article and method for making same |
US5591409A (en) * | 1995-08-15 | 1997-01-07 | Watkins; Carl J. | Providing aromas |
US5592934A (en) * | 1990-08-02 | 1997-01-14 | The Boc Group Plc | Anaesthetic vaporizer |
US5593792A (en) * | 1991-06-28 | 1997-01-14 | R. J. Reynolds Tobacco Company | Electrochemical heat source |
US5605146A (en) * | 1993-11-29 | 1997-02-25 | Instrumentarium Oy | Method and an arrangement in connection with vaporizing an anaesthetic |
US5613505A (en) * | 1992-09-11 | 1997-03-25 | Philip Morris Incorporated | Inductive heating systems for smoking articles |
US5738865A (en) * | 1995-04-07 | 1998-04-14 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US5743251A (en) * | 1996-05-15 | 1998-04-28 | Philip Morris Incorporated | Aerosol and a method and apparatus for generating an aerosol |
US5767117A (en) * | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
US5769621A (en) * | 1997-05-23 | 1998-06-23 | The Regents Of The University Of California | Laser ablation based fuel ignition |
US5874841A (en) * | 1997-07-28 | 1999-02-23 | Philips Electronics North America Corporation | Sample-and-hold circuit for a switched-mode power supply |
US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
US5894841A (en) * | 1993-06-29 | 1999-04-20 | Ponwell Enterprises Limited | Dispenser |
US5904900A (en) * | 1995-04-28 | 1999-05-18 | Etat Francais As Represented By Le Delegue General Pour L'armement | Device for sampling gaseous substances, liquids, aerosols or even powdered materials for in situ analysis |
US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
US6050260A (en) * | 1996-12-02 | 2000-04-18 | Fisher & Paykel Limited | Humidifier sleep apnea treatment apparatus |
US6051566A (en) * | 1991-02-09 | 2000-04-18 | B.S.D. Bio Science Development Snc Di Omini C. & Zuccari G. | Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation |
US6053176A (en) * | 1999-02-23 | 2000-04-25 | Philip Morris Incorporated | Heater and method for efficiently generating an aerosol from an indexing substrate |
US6178969B1 (en) * | 1998-03-03 | 2001-01-30 | Brown & Williamson Tobacco Corporation | Aerosol delivery smoking article |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US20020031480A1 (en) * | 1998-10-27 | 2002-03-14 | Joanne Peart | Delta9 tetrahydrocannabinol (Delta9 THC) solution metered dose inhalers and methods of use |
US20020037828A1 (en) * | 1997-10-28 | 2002-03-28 | Wilson Leland F. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US6376550B1 (en) * | 1999-02-09 | 2002-04-23 | Asta Medica Ag | Pharmaceutical compositions containing tramadol for migraine |
US20020058009A1 (en) * | 2000-09-19 | 2002-05-16 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6390453B1 (en) * | 1997-10-22 | 2002-05-21 | Microfab Technologies, Inc. | Method and apparatus for delivery of fragrances and vapors to the nose |
US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US20030004142A1 (en) * | 2001-04-18 | 2003-01-02 | Prior Christopher P. | Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway |
US6506762B1 (en) * | 1999-09-30 | 2003-01-14 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
US6514482B1 (en) * | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6516796B1 (en) * | 1998-10-14 | 2003-02-11 | Chrysalis Technologies Incorporated | Aerosol generator and methods of making and using an aerosol generator |
US20030033055A1 (en) * | 2001-07-31 | 2003-02-13 | Mcrae Douglas D. | Method and apparatus for generating a volatilized liquid |
US20030049025A1 (en) * | 2000-01-13 | 2003-03-13 | Hermann Neumann | Chip that comprises an active agent and an integrated heating element |
US6561186B2 (en) * | 1995-08-02 | 2003-05-13 | Innovative Devices | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
US6568390B2 (en) * | 2001-09-21 | 2003-05-27 | Chrysalis Technologies Incorporated | Dual capillary fluid vaporizing device |
US6671945B2 (en) * | 2001-01-19 | 2004-01-06 | Vishay Intertechnology, Inc. | Method for making a resistor using resistive foil |
US20040009128A1 (en) * | 2002-05-13 | 2004-01-15 | Rabinowitz Joshua D | Delivery of drug amines through an inhalation route |
US6681998B2 (en) * | 2000-12-22 | 2004-01-27 | Chrysalis Technologies Incorporated | Aerosol generator having inductive heater and method of use thereof |
US6681769B2 (en) * | 2001-12-06 | 2004-01-27 | Crysalis Technologies Incorporated | Aerosol generator having a multiple path heater arrangement and method of use thereof |
US20040016427A1 (en) * | 2000-04-27 | 2004-01-29 | Byron Peter R. | Method and apparatus for generating an aerosol |
US6688313B2 (en) * | 2000-03-23 | 2004-02-10 | Philip Morris Incorporated | Electrical smoking system and method |
US6694975B2 (en) * | 1996-11-21 | 2004-02-24 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US20040035409A1 (en) * | 2002-06-06 | 2004-02-26 | Harwig Jeffrey L. | Localized surface volatilization |
US6701922B2 (en) * | 2001-12-20 | 2004-03-09 | Chrysalis Technologies Incorporated | Mouthpiece entrainment airflow control for aerosol generators |
US6701921B2 (en) * | 2000-12-22 | 2004-03-09 | Chrysalis Technologies Incorporated | Aerosol generator having heater in multilayered composite and method of use thereof |
US20040055504A1 (en) * | 2001-10-15 | 2004-03-25 | Lee Brian Craig | Electro-thermal odor-releasing inks and methods for releasing odors from the same |
US6728478B2 (en) * | 2002-02-21 | 2004-04-27 | Dekko Heating Technologies, Inc. | Heated chemical delivery system |
US20040081624A1 (en) * | 2002-09-06 | 2004-04-29 | Chrysalis Technologies Incorporated | Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols |
US6737042B2 (en) * | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US20040099266A1 (en) * | 2002-11-27 | 2004-05-27 | Stephen Cross | Inhalation device for producing a drug aerosol |
US20070031340A1 (en) * | 2001-05-24 | 2007-02-08 | Hale Ron L | Thin-film drug delivery article and method of use |
US20070028916A1 (en) * | 2001-05-24 | 2007-02-08 | Hale Ron L | Rapid-heating drug delivery article and method of use |
Family Cites Families (462)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1239634A (en) | 1916-07-25 | 1917-09-11 | Frank J Stuart | Medical appliance. |
US2086140A (en) | 1933-09-08 | 1937-07-06 | Silten Ernst | Automatic temperature regulated narcosis apparatus |
US2084299A (en) | 1934-12-15 | 1937-06-15 | Arthur G Borden | Medicament holder for nasal inhalers |
US2230753A (en) | 1937-02-15 | 1941-02-04 | Bilhuber Corp E | Unsaturated ethylamine derivatives |
US2230754A (en) | 1937-02-15 | 1941-02-04 | Bilhuber Corp E | Unsaturated ethylamine derivatives |
GB502761A (en) | 1938-01-29 | 1939-03-24 | Christopher Engelbreth | Improvements in and relating to hand inhalation apparatus |
FR921852A (fr) | 1945-12-06 | 1947-05-21 | Diffuseur de produits volatils | |
US2714649A (en) | 1952-11-25 | 1955-08-02 | Lyle H Critzer | Vaporizer |
US2761055A (en) | 1953-06-10 | 1956-08-28 | Malcome Van Ike | Lamp-heated vaporizer |
US2741812A (en) * | 1954-02-15 | 1956-04-17 | Tellier Andre | Perfume dispenser |
US2902484A (en) | 1954-04-27 | 1959-09-01 | Rhone Poulenc Sa | Phenthiazine derivatives and processes for their preparation |
US2898649A (en) | 1956-11-19 | 1959-08-11 | Elaine T Cassidy | Perfume diffuser |
US3371085A (en) | 1959-12-10 | 1968-02-27 | Hoffmann La Roche | 5-aryl-3h-1,4-benzodiazepin-2(1h)-ones |
US3043977A (en) | 1960-03-30 | 1962-07-10 | Puritron Corp | Device and method for producing negative ions |
GB903866A (en) | 1961-05-09 | 1962-08-22 | Dausse Lab | Therapeutic preparations containing 7-substituted theophylline derivatives |
US3299185A (en) | 1962-09-27 | 1967-01-17 | Ube Nitto Kasei Co | Dyeable polyolefin fibers containing a binary copolymer of styrene and acrylonitrile |
NL289785A (de) | 1962-11-29 | |||
US3282729A (en) | 1963-02-27 | 1966-11-01 | Union Carbide Corp | Barrier coated thermoplastic olefin polymer substrates |
US3200819A (en) | 1963-04-17 | 1965-08-17 | Herbert A Gilbert | Smokeless non-tobacco cigarette |
NL298071A (de) | 1963-06-04 | |||
IL26896A (en) | 1966-01-19 | 1970-11-30 | Endo Lab | 14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones |
US3909463A (en) | 1968-11-29 | 1975-09-30 | Allied Chem | Grafted block copolymers of synthetic rubbers and polyolefins |
US3987052A (en) | 1969-03-17 | 1976-10-19 | The Upjohn Company | 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines |
US4008723A (en) | 1970-03-23 | 1977-02-22 | Imperial Chemical Industries Limited | Smoking mixture |
US3863347A (en) * | 1970-04-13 | 1975-02-04 | Philip Michael Banner | Navigation device |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3831606A (en) | 1971-02-19 | 1974-08-27 | Alza Corp | Auto inhaler |
US3847650A (en) | 1971-09-09 | 1974-11-12 | Airco Inc | Flashlamp with improved combustion foil and method of making same |
US3749547A (en) | 1971-09-09 | 1973-07-31 | Airco Inc | Flashlamp with improved combustible foil |
US4166087A (en) | 1971-11-22 | 1979-08-28 | Cline-Buckner, Inc. | Automatic intermittent vapor dispenser |
US3701782A (en) | 1972-02-10 | 1972-10-31 | Upjohn Co | 1-carbolower alkoxy - 6 - phenyl-4h-s-triazolo(1,4)benzodiazepine compounds |
US3763347A (en) | 1972-04-13 | 1973-10-02 | Ncr Co | Vaporous lamp |
IE37524B1 (en) | 1972-04-20 | 1977-08-17 | Gallaher Ltd | Synthetic smoking product |
US3864326A (en) | 1972-05-22 | 1975-02-04 | Robert S Babington | Spraying devices, in particular nebulizing devices |
USRE30285E (en) | 1972-05-22 | 1980-05-27 | Spraying devices, in particular nebulizing devices | |
GB1366041A (en) | 1972-07-21 | 1974-09-11 | Kodama Bros Co Ltd | Device for volatilizing insecticides and the like |
US3773995A (en) | 1972-10-27 | 1973-11-20 | Westinghouse Electric Corp | Motor advanced spring charging pawl and ratchet mechanism with spring assist |
US3982095A (en) | 1973-10-04 | 1976-09-21 | Searle Cardio-Pulmonary Systems Inc. | Respiratory humidifier |
US3971377A (en) | 1974-06-10 | 1976-07-27 | Alza Corporation | Medicament dispensing process for inhalation therapy |
US3894040A (en) | 1974-09-16 | 1975-07-08 | American Home Prod | 2,5,6,7-Tetrahydro-3H-imidazo(1,2-D)(1,4)benzodiazepine-5,6-dicarboxylic acid esters |
US4045156A (en) | 1974-12-23 | 1977-08-30 | Gte Sylvania Incorporated | Photoflash lamp |
US4104210A (en) | 1975-12-17 | 1978-08-01 | Monsanto Company | Thermoplastic compositions of high unsaturation diene rubber and polyolefin resin |
US4121583A (en) | 1976-07-13 | 1978-10-24 | Wen Yuan Chen | Method and apparatus for alleviating asthma attacks |
US4286604A (en) | 1976-10-05 | 1981-09-01 | Gallaher Limited | Smoking materials |
US4079742A (en) | 1976-10-20 | 1978-03-21 | Philip Morris Incorporated | Process for the manufacture of synthetic smoking materials |
US4160765A (en) | 1976-11-17 | 1979-07-10 | Smithkline Corporation | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
US4141369A (en) | 1977-01-24 | 1979-02-27 | Burruss Robert P | Noncombustion system for the utilization of tobacco and other smoking materials |
DE2752384A1 (de) | 1977-08-29 | 1979-03-15 | Simes | Pharmazeutisches praeparat auf der basis beklemmungsloesender mittel und hemmstoffe der beta-adrenergischen rezeptoren |
SE7812207L (sv) | 1977-12-01 | 1979-06-02 | Welsh Nat School Med | Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer |
JPS54120065A (en) | 1978-02-24 | 1979-09-18 | Osaka Takeshi | Stick for blind person |
US4198200A (en) | 1978-05-18 | 1980-04-15 | Lord Corporation | Damage-preventive coatings |
US4284089A (en) | 1978-10-02 | 1981-08-18 | Ray Jon P | Simulated smoking device |
US4280629A (en) | 1979-01-08 | 1981-07-28 | Anchor Brush Company, Inc. | Container for nail polish or the like |
US4219031A (en) | 1979-03-05 | 1980-08-26 | Philip Morris Incorporated | Smoking product having core of fibrillar carbonized matter |
US4229931A (en) | 1979-03-05 | 1980-10-28 | Deere & Company | Hydraulic height sensing system with cylinder by-pass |
IL59407A (en) | 1979-03-06 | 1983-12-30 | Sanofi Sa | Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them |
US4654370A (en) | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
US4251525A (en) | 1979-05-25 | 1981-02-17 | Smithkline Corporation | 3-Allyl-7,8-dihydroxy-6-halo-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives |
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
GB2064296B (en) | 1979-11-16 | 1983-06-22 | Imp Group Ltd | Cigarette or cigarette-like device which produces aerosol in smoke |
ATE3774T1 (de) | 1980-05-02 | 1983-06-15 | Schering Corporation | Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung. |
US4391285A (en) | 1980-05-09 | 1983-07-05 | Philip Morris, Incorporated | Smoking article |
US4347855A (en) | 1980-07-23 | 1982-09-07 | Philip Morris Incorporated | Method of making smoking articles |
US4303083A (en) | 1980-10-10 | 1981-12-01 | Burruss Jr Robert P | Device for evaporation and inhalation of volatile compounds and medications |
US4376767A (en) | 1981-01-02 | 1983-03-15 | Merck & Co., Inc. | Pyridylmethyl esters of selected bio-affecting carboxylic acids |
US4346059A (en) | 1981-03-03 | 1982-08-24 | Donald Spector | Aroma-generating lamp structure |
DE3116951C2 (de) * | 1981-04-29 | 1984-12-20 | Drägerwerk AG, 2400 Lübeck | Vorrichtung zur Beimischung flüssiger Narkosemittel in das dem Patienten zuzuführende Atemgas |
JPS5876038A (ja) | 1981-10-28 | 1983-05-09 | 高森 正之 | 殺虫剤や芳香剤の蒸発装置 |
GB2122903B (en) | 1982-06-22 | 1986-11-05 | Masayuki Takamori | Vaporizers for vaporisable substances and support media for substances usable therewith |
DE3224849A1 (de) | 1982-07-02 | 1984-01-05 | Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn | Dampfinhaliergeraet |
US4556539A (en) | 1982-08-27 | 1985-12-03 | Donald Spector | Disc-playing aroma generator |
US4508726A (en) * | 1982-09-16 | 1985-04-02 | The Upjohn Company | Treatment of panic disorders with alprazolam |
CH665750A5 (de) | 1982-09-30 | 1988-06-15 | Dainippon Jochugiku Kk | Beheizbarer wirkstoffverdampfer. |
US4474191A (en) | 1982-09-30 | 1984-10-02 | Steiner Pierre G | Tar-free smoking devices |
US4753758A (en) | 1983-05-19 | 1988-06-28 | Intertech Resources Inc. | Respiratory humidifier |
US5038769A (en) | 1983-06-29 | 1991-08-13 | Krauser Robert S | Method and apparatus for treating ailments |
US4523589A (en) | 1983-06-29 | 1985-06-18 | Krauser Robert S | Method and apparatus for treating ailments |
DE3326089A1 (de) | 1983-07-20 | 1985-02-07 | Gödecke AG, 1000 Berlin | Zur inhalation bestimmte darreichungsform von calcium-antagonisten |
DE3476197D1 (en) | 1983-08-01 | 1989-02-23 | Mclean Hospital Corp | Gaba esters and gaba analogue esters |
ATE44470T1 (de) | 1983-11-08 | 1989-07-15 | Bunnell Life Systems Inc | Befeuchter, insbesondere fuer atmungshilfesysteme. |
FI68988C (fi) * | 1984-01-04 | 1985-12-10 | Rauma Repola Oy | Flissikt vars siktkorg delats i tvao korgsektorer |
GB8405190D0 (en) | 1984-02-28 | 1984-04-04 | British Petroleum Co Plc | Thermoplastic elastomer composition |
US4627963A (en) | 1984-02-29 | 1986-12-09 | Lad Technology, Inc. | Heat activated dispenser and method of dispensing a vapor therefrom |
US4683231A (en) | 1984-03-02 | 1987-07-28 | Research Foundation For Mental Hygiene, Inc. | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking |
DE3414640A1 (de) * | 1984-04-18 | 1985-10-24 | W. Schlafhorst & Co, 4050 Mönchengladbach | Rotations-schaftmaschine |
US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4755508A (en) | 1984-06-26 | 1988-07-05 | Merck & Co., Inc. | Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin |
US4793365A (en) | 1984-09-14 | 1988-12-27 | R. J. Reynolds Tobacco Company | Smoking article |
US5067499A (en) | 1984-09-14 | 1991-11-26 | R. J. Reynolds Tobacco Company | Smoking article |
US4854331A (en) | 1984-09-14 | 1989-08-08 | R. J. Reynolds Tobacco Company | Smoking article |
US5020548A (en) | 1985-08-26 | 1991-06-04 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
US5042509A (en) | 1984-09-14 | 1991-08-27 | R. J. Reynolds Tobacco Company | Method for making aerosol generating cartridge |
CN1018329B (zh) | 1984-12-21 | 1992-09-23 | 美国耳杰瑞诺兹烟草公司 | 吸烟制品的碳燃料元件及其制备方法 |
GB8501015D0 (en) | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
US4928714A (en) | 1985-04-15 | 1990-05-29 | R. J. Reynolds Tobacco Company | Smoking article with embedded substrate |
US5119834A (en) | 1985-04-15 | 1992-06-09 | R. J. Reynolds Tobacco Company | Smoking article with improved substrate |
ATE78158T1 (de) | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
US4800903A (en) | 1985-05-24 | 1989-01-31 | Ray Jon P | Nicotine dispenser with polymeric reservoir of nicotine |
US4989619A (en) | 1985-08-26 | 1991-02-05 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
US5105831A (en) | 1985-10-23 | 1992-04-21 | R. J. Reynolds Tobacco Company | Smoking article with conductive aerosol chamber |
US4756318A (en) | 1985-10-28 | 1988-07-12 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US5033483A (en) | 1985-10-28 | 1991-07-23 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US5060666A (en) | 1985-10-28 | 1991-10-29 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US4793366A (en) | 1985-11-12 | 1988-12-27 | Hill Ira D | Nicotine dispensing device and methods of making the same |
US4863720A (en) | 1986-03-10 | 1989-09-05 | Walter Burghart | Pharmaceutical preparation and methods for its production |
US4708151A (en) | 1986-03-14 | 1987-11-24 | R. J. Reynolds Tobacco Company | Pipe with replaceable cartridge |
US4765347A (en) | 1986-05-09 | 1988-08-23 | R. J. Reynolds Tobacco Company | Aerosol flavor delivery system |
US4771795A (en) | 1986-05-15 | 1988-09-20 | R. J. Reynolds Tobacco Company | Smoking article with dual burn rate fuel element |
US4917120A (en) | 1986-05-21 | 1990-04-17 | Advanced Tobacco Products, Inc. | Nicotine impact modification |
US4774971A (en) | 1986-06-03 | 1988-10-04 | Vieten Michael J | Cigarette substitute |
US4801411A (en) | 1986-06-05 | 1989-01-31 | Southwest Research Institute | Method and apparatus for producing monosize ceramic particles |
US4735217A (en) | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
US4858630A (en) | 1986-12-08 | 1989-08-22 | R. J. Reynolds Tobacco Company | Smoking article with improved aerosol forming substrate |
IL84516A0 (en) | 1986-12-12 | 1988-04-29 | Reynolds Tobacco Co R | Smoking articles comprising impact modifying agents |
US4734560A (en) | 1987-01-20 | 1988-03-29 | Medical Enterprises, Ltd. | Vaporizing unit |
US4819665A (en) | 1987-01-23 | 1989-04-11 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US4968885A (en) | 1987-03-06 | 1990-11-06 | Extrel Corporation | Method and apparatus for introduction of liquid effluent into mass spectrometer and other gas-phase or particle detectors |
HU201685B (en) | 1987-04-23 | 1990-12-28 | Chinoin Gyogyszer Es Vegyeszet | For producing pharmaceutical compositions for inhalation and compositions for scenting air containing volatile active component in cyclodextrine inclusion, and air-scenting composition |
US4889850A (en) | 1987-05-11 | 1989-12-26 | Thornfeldt Carl R | Treatment of colic and teething |
GB8713645D0 (en) | 1987-06-11 | 1987-07-15 | Imp Tobacco Ltd | Smoking device |
US5019122A (en) | 1987-08-21 | 1991-05-28 | R. J. Reynolds Tobacco Company | Smoking article with an enclosed heat conductive capsule containing an aerosol forming substance |
US5072726A (en) | 1987-10-09 | 1991-12-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Vaporizer for inhalation anesthetics during high-frequency jet ventilation and associated method |
US4906417A (en) | 1988-02-08 | 1990-03-06 | Associated Mills Inc. | Humidifier |
JPH01221313A (ja) | 1988-02-29 | 1989-09-04 | Hayashi Teruaki | 昇華放出薬剤組成物とその放出システム |
US4853517A (en) | 1988-03-28 | 1989-08-01 | John G. Bowen | Vaporizing unit |
US5137034A (en) | 1988-05-16 | 1992-08-11 | R. J. Reynolds Tobacco Company | Smoking article with improved means for delivering flavorants |
US4881556A (en) | 1988-06-06 | 1989-11-21 | R. J. Reynolds Tobacco Company | Low CO smoking article |
US5264433A (en) | 1988-07-07 | 1993-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
CH678151A5 (en) | 1988-07-13 | 1991-08-15 | Heinz Hermann Weick | Self-medication nasal dispenser |
US5345951A (en) | 1988-07-22 | 1994-09-13 | Philip Morris Incorporated | Smoking article |
US4852561A (en) | 1988-07-27 | 1989-08-01 | Sperry C R | Inhalation device |
US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
EP0358114A3 (de) | 1988-09-08 | 1990-11-14 | R.J. Reynolds Tobacco Company | Elektrisches Gerät zur Verabreichung von Aerosol |
US4947874A (en) | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Smoking articles utilizing electrical energy |
US4947875A (en) | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Flavor delivery articles utilizing electrical energy |
USRE36744E (en) | 1988-09-16 | 2000-06-20 | Ribogene, Inc. | Nasal administration of benzodiazepine hypnotics |
US4950664A (en) | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
US4917830A (en) | 1988-09-19 | 1990-04-17 | The United States Of America As Represented By The United States Department Of Energy | Monodisperse aerosol generator |
US4963289A (en) | 1988-09-19 | 1990-10-16 | The United States Of America As Represented By The United States Department Of Energy | Method for producing monodisperse aerosols |
US5511726A (en) | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
HU200105B (en) | 1988-10-04 | 1990-04-28 | Ferenc Inkovics | Electrically actuated inhaler of uniform medicine feeding |
US4917119A (en) | 1988-11-30 | 1990-04-17 | R. J. Reynolds Tobacco Company | Drug delivery article |
US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
US4959380A (en) | 1988-12-19 | 1990-09-25 | Wilson Jordan E | Method of treating people to stop smoking and composition |
US4881541A (en) | 1988-12-21 | 1989-11-21 | The Regents Of The University Of California | Vaporizer for an anesthetic having a vapor pressure about one atmosphere |
GB8900267D0 (en) | 1989-01-06 | 1989-03-08 | Riker Laboratories Inc | Narcotic analgesic formulations and apparatus containing same |
DE3908161A1 (de) | 1989-03-13 | 1990-09-27 | Bat Cigarettenfab Gmbh | Rauchbarer artikel |
EP0470154B1 (de) | 1989-04-28 | 1996-06-05 | Riker Laboratories, Inc. | Inhalationsvorrichtung für trockenpulver |
GB8909891D0 (en) | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
CA2054197A1 (en) | 1989-05-05 | 1990-11-06 | Christopher O'neill | Fertility enhancement |
US4941483A (en) | 1989-09-18 | 1990-07-17 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
US6313176B1 (en) | 1989-10-17 | 2001-11-06 | Everett J. Ellinwood, Jr. | Dosing method of administering deprenyl via intraoral administration or inhalation administration |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5269327A (en) | 1989-12-01 | 1993-12-14 | Philip Morris Incorporated | Electrical smoking article |
US5060671A (en) | 1989-12-01 | 1991-10-29 | Philip Morris Incorporated | Flavor generating article |
US5144962A (en) | 1989-12-01 | 1992-09-08 | Philip Morris Incorporated | Flavor-delivery article |
US5224498A (en) | 1989-12-01 | 1993-07-06 | Philip Morris Incorporated | Electrically-powered heating element |
ATE156704T1 (de) | 1989-12-05 | 1997-08-15 | Ramsey Foundation | Neurologische wirkstoffe zur nasalen verabreichung an das gehirn |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
GB9000042D0 (en) * | 1990-01-03 | 1990-03-07 | Ralph John F | Decorative wall covering applied to steel radiators |
GB2239807A (en) * | 1990-01-09 | 1991-07-17 | Boc Group Plc | Anaesthetic vaporiser |
US5376386A (en) | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
US5099861A (en) | 1990-02-27 | 1992-03-31 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US5156170A (en) | 1990-02-27 | 1992-10-20 | R. J. Reynolds Tobacco Company | Cigarette |
GB9004781D0 (en) * | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
US5118494A (en) | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US5366770A (en) | 1990-04-17 | 1994-11-22 | Xingwu Wang | Aerosol-plasma deposition of films for electronic cells |
US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5192548A (en) | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
RU2160736C2 (ru) | 1990-06-07 | 2000-12-20 | Зенека Лимитед | Производные индола и их физиологически приемлемые соли и сольваты, способы их получения, лекарственное средство для лечения или профилактики клинических состояний, для которых показан прием агониста "5-нт1-подобного" рецептора, и способ его получения |
SE9002052D0 (sv) | 1990-06-08 | 1990-06-08 | Pharmacia Ab | Smoking composition |
US5167242A (en) | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
US5455043A (en) | 1990-06-13 | 1995-10-03 | Fischel-Ghodsian; Fariba | Device for controlled release of vaporous medications through nasal route |
US5060667A (en) | 1990-08-16 | 1991-10-29 | Brown & Williamson Tobacco Corporation | Smoking article |
US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
US5166202A (en) | 1990-09-19 | 1992-11-24 | Trustees Of The University Of Pennsylvania | Method for the treatment of panic disorder |
NO904226D0 (no) | 1990-09-28 | 1990-09-28 | Forsvarets Forsknings | Fukteanordning. |
US5175152A (en) | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
HU219778B (hu) | 1990-12-21 | 2001-07-30 | Gyógyszerkutató Intézet Közös Vállalat | Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények |
US5519019A (en) | 1990-12-21 | 1996-05-21 | Gyogyszerkutato Intezet | N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same |
FR2671487B1 (fr) | 1991-01-14 | 1993-03-19 | Oreal | Utilisation d'un facteur de croissance dans une composition amincissante. |
ES2179068T3 (es) | 1991-03-05 | 2003-01-16 | Aradigm Corp | Metodo y dispositivo para corregir el desplazamiento de deriva de un detector de presion de flujo. |
US5469750A (en) | 1991-03-05 | 1995-11-28 | Aradigm Corporation | Method and apparatus for sensing flow in two directions and automatic calibration thereof |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5226411A (en) | 1991-03-07 | 1993-07-13 | Walter Levine | Aerosol nebulizer heater |
US5249586A (en) | 1991-03-11 | 1993-10-05 | Philip Morris Incorporated | Electrical smoking |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
US5817656A (en) | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Mental disorders |
US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5605897A (en) | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
US5164740A (en) | 1991-04-24 | 1992-11-17 | Yehuda Ivri | High frequency printing mechanism |
US5938117A (en) | 1991-04-24 | 1999-08-17 | Aerogen, Inc. | Methods and apparatus for dispensing liquids as an atomized spray |
GB9109021D0 (en) | 1991-04-26 | 1991-06-12 | Boc Group Plc | Dosing pump |
US5261424A (en) | 1991-05-31 | 1993-11-16 | Philip Morris Incorporated | Control device for flavor-generating article |
US5160664A (en) * | 1991-05-31 | 1992-11-03 | Msp Corporation | High output monodisperse aerosol generator |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
US5177071A (en) | 1991-06-17 | 1993-01-05 | Merck & Co., Inc. | 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder |
CN1103609C (zh) * | 1991-08-07 | 2003-03-26 | 伊万·菲利普·吉勒·佩森蒂 | 吸入装置 |
US5184133A (en) * | 1991-11-26 | 1993-02-02 | Texas Instruments Incorporated | ISAR imaging radar system |
US5457100A (en) | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
US5363842A (en) | 1991-12-20 | 1994-11-15 | Circadian, Inc. | Intelligent inhaler providing feedback to both patient and medical professional |
GB9200047D0 (en) | 1992-01-03 | 1992-02-26 | Univ Alberta | Nicotine-containing nasal spray |
US5229120A (en) | 1992-02-05 | 1993-07-20 | Devincent James F | Treatment for ***e abuse |
US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
DK64592D0 (da) | 1992-05-14 | 1992-05-14 | Carlbiotech Ltd As | Peptider til terapeutisk behandling |
US5391081A (en) | 1992-05-13 | 1995-02-21 | University Of Florida Research Foundation, Incorporated | Method and apparatus for simulating neuromuscular stimulation during medical surgery |
US5584701A (en) | 1992-05-13 | 1996-12-17 | University Of Florida Research Foundation, Incorporated | Self regulating lung for simulated medical procedures |
US5525329A (en) | 1992-05-21 | 1996-06-11 | The Johns Hopkins University | Inhibition of phosphodiesterase in olfactory mucosa |
DE69330672T2 (de) | 1992-06-12 | 2002-06-27 | Teijin Ltd | Pharmazeutische zubereitung zur anwendung in den atemwegen |
US5622944A (en) | 1992-06-12 | 1997-04-22 | Affymax Technologies N.V. | Testosterone prodrugs for improved drug delivery |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5284133A (en) | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
US5333106A (en) | 1992-10-09 | 1994-07-26 | Circadian, Inc. | Apparatus and visual display method for training in the power use of aerosol pharmaceutical inhalers |
WO1994009842A1 (en) * | 1992-10-28 | 1994-05-11 | Rosen Charles A | Method and devices for delivering drugs by inhalation |
US5672581A (en) | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
US6098620A (en) | 1993-01-29 | 2000-08-08 | Aradigm Corporation | Device for aerosolizing narcotics |
US5915378A (en) | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
US5888477A (en) | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
US5507277A (en) | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
US5364838A (en) | 1993-01-29 | 1994-11-15 | Miris Medical Corporation | Method of administration of insulin |
US5743250A (en) | 1993-01-29 | 1998-04-28 | Aradigm Corporation | Insulin delivery enhanced by coached breathing |
US6024090A (en) | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
US5724957A (en) | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
US5970973A (en) | 1993-01-29 | 1999-10-26 | Aradigm Corporation | Method of delivering insulin lispro |
US5694919A (en) | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5372148A (en) | 1993-02-24 | 1994-12-13 | Philip Morris Incorporated | Method and apparatus for controlling the supply of energy to a heating load in a smoking article |
US5468936A (en) | 1993-03-23 | 1995-11-21 | Philip Morris Incorporated | Heater having a multiple-layer ceramic substrate and method of fabrication |
GB9310412D0 (en) | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
CN1082365A (zh) | 1993-05-25 | 1994-02-23 | 潘昆年 | 营养保健香烟 |
WO1994028959A1 (de) | 1993-06-03 | 1994-12-22 | Barthold Von Schrader | Inhalationseinrichtung |
US5666977A (en) | 1993-06-10 | 1997-09-16 | Philip Morris Incorporated | Electrical smoking article using liquid tobacco flavor medium delivery system |
US5388574A (en) * | 1993-07-29 | 1995-02-14 | Ingebrethsen; Bradley J. | Aerosol delivery article |
DE4328243C1 (de) | 1993-08-19 | 1995-03-09 | Sven Mielordt | Rauch- oder Inhalationsvorrichtung |
US5456247A (en) | 1993-08-26 | 1995-10-10 | Iowa State University Research Foundation, Inc. | Method for delivering drugs soluble in a vaporization vehicle |
US5462740A (en) | 1993-09-17 | 1995-10-31 | Athena Neurosciences, Inc. | Rectally-administered, epileptic-seizure-inhibiting composition |
SE9303574D0 (sv) | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method the manufacturing thereof |
MA23420A1 (fr) | 1994-01-07 | 1995-10-01 | Smithkline Beecham Corp | Antagonistes bicycliques de fibrinogene. |
US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
US5522008A (en) | 1994-03-16 | 1996-05-28 | Bernard; Costello J. | Device for heating and vaporizing a vaporizable module |
US5451408A (en) | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
JPH09511248A (ja) | 1994-03-30 | 1997-11-11 | ザ、プロクター、エンド、ギャンブル、カンパニー | 混合スキンモイスチャライジング及びクレンジング固形組成物 |
US6102036A (en) | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
EP0759744B1 (de) | 1994-05-13 | 2001-10-17 | Aradigm Corporation | Ein narkotikum enthaltende aerosolformulierung |
US5457101A (en) | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
MA23588A1 (fr) | 1994-06-23 | 1995-12-31 | Procter & Gamble | Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme |
WO1996000069A1 (en) | 1994-06-23 | 1996-01-04 | The Procter & Gamble Company | Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration |
MA23587A1 (fr) | 1994-06-23 | 1995-12-31 | Procter & Gamble | Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme |
CA2152684A1 (en) | 1994-07-01 | 1996-01-02 | Richard Anthony Henry | Aerosol delivery of midazolam |
DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
WO1996006087A1 (en) | 1994-08-22 | 1996-02-29 | Smithkline Beecham Corporation | Bicyclic compounds |
US5456677A (en) | 1994-08-22 | 1995-10-10 | Spector; John E. | Method for oral spray administration of caffeine |
US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5537507A (en) | 1994-09-28 | 1996-07-16 | Advanced Ceramics Corporation | Coated flash evaporator heater |
AU3380395A (en) | 1994-09-30 | 1996-04-26 | Niro Separation A/S | A plant and a process for dry-producing a web-formed product |
DE69524623T2 (de) | 1994-10-14 | 2002-08-08 | Glaxo Wellcome Spa | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen |
EP1177807A3 (de) | 1994-10-28 | 2003-10-22 | Aradigm Corporation | Vorrichtung und Verfahren zum Herstellen von Aerosolnebel aus einem atmungserleichternden Arzneimittel |
US5540959A (en) | 1995-02-21 | 1996-07-30 | Howard J. Greenwald | Process for preparing a coated substrate |
WO1996025918A1 (en) | 1995-02-24 | 1996-08-29 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
DE19507410C2 (de) | 1995-03-03 | 1997-05-22 | Gsf Forschungszentrum Umwelt | Verfahren und Vorrichtung zur Herstellung von Aerosolen |
US5565148A (en) | 1995-03-16 | 1996-10-15 | Minnesota Mining And Manufacturing Company | Device for selectively providing a multiplicity of aromas |
EP0817655B1 (de) | 1995-03-31 | 2004-05-19 | Aradigm Corporation | Intrapulmonare verabreichung vom hematopoietischem medikament |
US5586550A (en) | 1995-08-31 | 1996-12-24 | Fluid Propulsion Technologies, Inc. | Apparatus and methods for the delivery of therapeutic liquids to the respiratory system |
US5758637A (en) | 1995-08-31 | 1998-06-02 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
US6014970A (en) | 1998-06-11 | 2000-01-18 | Aerogen, Inc. | Methods and apparatus for storing chemical compounds in a portable inhaler |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
EP1870122A3 (de) | 1995-04-14 | 2008-03-12 | SmithKline Beecham Corporation | Inhalator für abgemessene Dosen |
JP3573213B2 (ja) | 1995-04-14 | 2004-10-06 | グラクソ、ウェルカム、インコーポレーテッド | ベクロメタゾンジプロピオネート用計量投与用吸入器 |
NZ306280A (en) | 1995-04-14 | 1999-07-29 | Glaxo Wellcome Inc | Metered dose inhaler for salmeterol |
US5725756A (en) | 1995-04-18 | 1998-03-10 | Center For Research, Inc. | In situ mitigation of coke buildup in porous catalysts with supercritical reaction media |
US5690809A (en) | 1995-04-18 | 1997-11-25 | Center For Research, Inc. | In situ mitigation of coke buildup in porous catalysts by pretreatment of hydrocarbon feed to reduce peroxides and oxygen impurities |
US5776928A (en) | 1995-04-21 | 1998-07-07 | Eli Lilly And Company | Method for treating dyskinesias with olanzapine |
US5809997A (en) | 1995-05-18 | 1998-09-22 | Medtrac Technologies, Inc. | Electronic medication chronolog device |
DE19519056A1 (de) | 1995-05-24 | 1997-01-16 | Klinge Co Chem Pharm Fab | Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation |
GB9512708D0 (en) | 1995-06-22 | 1995-08-23 | Reckitt & Colman Inc | Improvements in or relating to organic compounds |
US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
SE9503141D0 (sv) | 1995-09-12 | 1995-09-12 | Siemens Elema Ab | Narkosapparat |
US5649554A (en) | 1995-10-16 | 1997-07-22 | Philip Morris Incorporated | Electrical lighter with a rotatable tobacco supply |
US6013050A (en) | 1995-10-20 | 2000-01-11 | Powderject Research Limited | Particle delivery |
WO1997016181A1 (en) | 1995-11-03 | 1997-05-09 | University Of Kentucky | Method for the intranasal administration of l-dopa prodrugs |
US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
US5564442A (en) | 1995-11-22 | 1996-10-15 | Angus Collingwood MacDonald | Battery powered nicotine vaporizer |
WO1997021426A1 (fr) | 1995-12-14 | 1997-06-19 | Taisho Pharmaceutical Co., Ltd. | Preparation aerosol |
AU1335397A (en) | 1995-12-21 | 1997-07-17 | Eli Lilly And Company | Method for treating dermatitis |
SE9504580L (sv) | 1995-12-21 | 1997-06-22 | Siemens Elema Ab | Förfarande vid förgasning av en narkosvätska och en förgasare |
CA2245079A1 (en) | 1996-02-05 | 1997-08-07 | Fred Silverstein | Ventilation imaging using a fine particle aerosol generator |
US5829436A (en) | 1996-02-05 | 1998-11-03 | Aradigm Corporation | Ventilation imaging using a fine particle aerosol generator |
DE19606107C1 (de) * | 1996-02-19 | 1997-02-13 | Martin Umwelt & Energietech | Feuerungsrost, insbesondere für Müllverbrennungsanlagen |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
GB9604329D0 (en) | 1996-02-29 | 1996-05-01 | Ici Plc | Electrostatic spraying |
EP0885038B1 (de) | 1996-03-01 | 2011-06-15 | The University Of Kansas | Methoden und vorrichtungen zur teilchenausfallung und -beschichtung mit fast kritischen oder uberkritischen anti-losungsmitteln |
US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
EP0828489A4 (de) | 1996-03-13 | 2001-04-04 | Univ Yale | Raucherentwöhnungsbehandlung unter verwendung von naltrexon und verwandten verbindungen |
GB9606188D0 (en) | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
US5944012A (en) | 1996-03-25 | 1999-08-31 | Pera; Ivo E. | Method for dispensing antioxidant vitamins by inhalation background of the invention |
GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
GB2312848B (en) | 1996-04-26 | 1999-11-17 | Bespak Plc | Controlled flow inhalers |
DE69724420T2 (de) | 1996-04-29 | 2004-06-09 | Quadrant Technologies Ltd. | Verfahren zum inhalieren trockener pulver |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5929093A (en) | 1996-06-13 | 1999-07-27 | Mayo Foundation For Medical Education And Research | Bifunctional acetylcholinesterase reactivators |
JP3413208B2 (ja) | 1996-06-17 | 2003-06-03 | 日本たばこ産業株式会社 | 香味生成物品及び香味生成器具 |
KR100264617B1 (ko) * | 1996-06-17 | 2000-09-01 | 미즈노 마사루 | 향미생성물품 |
US6089857A (en) | 1996-06-21 | 2000-07-18 | Japan Tobacco, Inc. | Heater for generating flavor and flavor generation appliance |
GB9613015D0 (en) | 1996-06-21 | 1996-08-28 | Reckitt & Colman Inc | Device |
WO1997049690A1 (en) | 1996-06-27 | 1997-12-31 | Merck & Co., Inc. | A method for treating meniere's disease |
IL127955A0 (en) | 1996-07-11 | 1999-11-30 | Farmarc Nederland Bv | Pharmaceutical composition containing acid addition salt of basic drug |
US6004516A (en) | 1996-08-06 | 1999-12-21 | Illinois Institute Of Technology | Apparatus for generating odor upon electronic signal demand |
US6325475B1 (en) | 1996-09-06 | 2001-12-04 | Microfab Technologies Inc. | Devices for presenting airborne materials to the nose |
DK0951280T3 (da) | 1996-10-03 | 2004-05-17 | Hermes Biosciences Inc | Hydrofile mikropartikler og fremgangsmåder til fremstilling heraf |
US5934289A (en) | 1996-10-22 | 1999-08-10 | Philip Morris Incorporated | Electronic smoking system |
US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US5878752A (en) | 1996-11-25 | 1999-03-09 | Philip Morris Incorporated | Method and apparatus for using, cleaning, and maintaining electrical heat sources and lighters useful in smoking systems and other apparatuses |
US5744469A (en) | 1996-11-26 | 1998-04-28 | Eli Lilly And Company | Method for treating dermatitis |
JP2001513078A (ja) | 1996-12-30 | 2001-08-28 | バテル・メモリアル・インスティテュート | 吸入により新生物を治療する製剤とその方法 |
ATE287257T1 (de) | 1997-01-16 | 2005-02-15 | Massachusetts Inst Technology | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
WO1998034595A1 (de) | 1997-02-05 | 1998-08-13 | Jago Research Ag | Medizinische aerosolformulierungen |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
US6051257A (en) | 1997-02-24 | 2000-04-18 | Superior Micropowders, Llc | Powder batch of pharmaceutically-active particles and methods for making same |
US6192882B1 (en) | 1997-02-24 | 2001-02-27 | Aradigm Corporation | Formulation and devices for monitoring the efficacy of the delivery of aerosols |
US5829435A (en) | 1997-02-24 | 1998-11-03 | Aradigm Corporation | Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles |
US5837713A (en) | 1997-02-26 | 1998-11-17 | Mayo Foundation For Medical Education And Research | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids |
HU219329B (en) | 1997-04-21 | 2001-03-28 | Radelkis Elektroanalitikai Mue | Ph-electrode based on glass material |
US5907075A (en) | 1997-06-11 | 1999-05-25 | The University Of Kansas | Solid acid supercritical alkylation reactions using carbon dioxide and/or other co-solvents |
US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
US5928520A (en) | 1997-07-16 | 1999-07-27 | Abanaki Corporation | Method and apparatus for extracting ground water contaiminants |
KR100289448B1 (ko) | 1997-07-23 | 2001-05-02 | 미즈노 마사루 | 향미발생장치 |
HUP9701284A3 (en) | 1997-07-24 | 2005-11-28 | Egyt Gyogyszervegyeszeti Gyar | Use of 2,3-benzodiazepine derivatives for producing pharmaceutical compositions for treating and prophylacting illnesses and conditions connected with the endogene opioide system |
US6090212A (en) * | 1997-08-15 | 2000-07-18 | Micro C Technologies, Inc. | Substrate platform for a semiconductor substrate during rapid high temperature processing and method of supporting a substrate |
US5855564A (en) | 1997-08-20 | 1999-01-05 | Aradigm Corporation | Aerosol extrusion mechanism |
US6250301B1 (en) | 1997-08-28 | 2001-06-26 | Hortal Harm B.V. | Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix |
CN1176075A (zh) | 1997-08-29 | 1998-03-18 | 宋国合 | 不燃烧***无毒香烟制品及其制备方法 |
US6138683A (en) | 1997-09-19 | 2000-10-31 | Thione International, Inc. | Smokeless tobacco products containing antioxidants |
DE69814428T2 (de) | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
ATE213246T1 (de) | 1997-11-12 | 2002-02-15 | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren | |
HUP0100277A3 (en) | 1998-01-27 | 2002-03-28 | American Cyanamid Company Madi | 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as metalloproteinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
US6044777A (en) | 1998-02-09 | 2000-04-04 | Walsh; Michael J. | Composite metal safe and method of making |
US6158431A (en) | 1998-02-13 | 2000-12-12 | Tsi Incorporated | Portable systems and methods for delivery of therapeutic material to the pulmonary system |
EP1080720A4 (de) | 1998-03-05 | 2002-06-05 | Nippon Shinyaku Co Ltd | Fettemulsionen zur inhalativen verabreichung |
ES2248985T3 (es) | 1998-03-05 | 2006-03-16 | Zivena, Inc. | Sistema de dosificacion pulmonar. |
PT1073432E (pt) | 1998-04-14 | 2007-10-22 | Gen Hospital Corp | Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia |
WO1999055362A1 (en) * | 1998-04-29 | 1999-11-04 | Genentech, Inc. | Spray dried formulations of igf-i |
GB9810559D0 (en) | 1998-05-15 | 1998-07-15 | Bradford Particle Design Ltd | Method and apparatus for particle formation |
US6060212A (en) * | 1998-06-11 | 2000-05-09 | Clariant Finance (Bvi) Limited | 193 nm positive-working photoresist composition |
WO1999064094A1 (en) | 1998-06-12 | 1999-12-16 | Aradigm Corporation | Methods of delivering aerosolized polynucleotides to the respiratory tract |
US6095153A (en) | 1998-06-19 | 2000-08-01 | Kessler; Stephen B. | Vaporization of volatile materials |
TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
US6090403A (en) | 1998-08-17 | 2000-07-18 | Lectec Corporation | Inhalation therapy decongestant with foraminous carrier |
WO2000019991A1 (en) | 1998-10-02 | 2000-04-13 | Battelle Memorial Institute | Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung |
US6255334B1 (en) | 1998-10-30 | 2001-07-03 | Pfizer Inc | 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
DE19854007C2 (de) | 1998-11-12 | 2001-05-17 | Reemtsma H F & Ph | System zur Bereitstellung eines inhalierbaren Aerosols |
IL143046A0 (en) | 1998-11-12 | 2002-04-21 | Pilkiewicz Frank G | An inhalation system |
DE19854012C2 (de) | 1998-11-12 | 2001-05-10 | Reemtsma H F & Ph | System zur Bereitstellung eines inhalierbaren Aerosols |
CA2347856C (en) | 1998-11-13 | 2009-02-17 | Jago Research Ag | Dry powder for inhalation |
US6070575A (en) | 1998-11-16 | 2000-06-06 | Aradigm Corporation | Aerosol-forming porous membrane with certain pore structure |
AU1473000A (en) | 1998-11-16 | 2000-06-05 | Aradigm Corporation | Method of fabricating porous membrane with unique pore structure for aerosolizeddelivery of drugs |
US6113795A (en) | 1998-11-17 | 2000-09-05 | The University Of Kansas | Process and apparatus for size selective separation of micro- and nano-particles |
JP3506618B2 (ja) | 1998-11-18 | 2004-03-15 | ウシオ電機株式会社 | 黄色光放射用白熱電球 |
WO2000035417A1 (en) | 1998-12-11 | 2000-06-22 | Pharmachemie B.V. | Pharmaceutical preparation for inhalation of an opioid |
WO2000038618A2 (en) | 1998-12-24 | 2000-07-06 | Du Pont Pharmaceuticals Company | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
AR022423A1 (es) | 1999-01-27 | 2002-09-04 | American Cyanamid Co | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento |
DK1031347T3 (da) | 1999-01-27 | 2002-07-08 | Idea Ag | Transnasal transport/immunisering med meget tilpasselige bærere |
WO2000047203A1 (en) | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
US6591839B2 (en) | 1999-02-17 | 2003-07-15 | Dieter Meyer | Filter material for reducing harmful substances in tobacco smoke |
AU3393600A (en) | 1999-03-05 | 2000-09-21 | Battelle Memorial Institute | Method for safely and effectively administering a drug by inhalation |
JP2002543092A (ja) | 1999-04-27 | 2002-12-17 | イーライ・リリー・アンド・カンパニー | 肺投与用インスリン結晶 |
MXPA01011052A (es) | 1999-04-30 | 2002-11-22 | Univ Michigan | Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas. |
ATE274955T1 (de) | 1999-05-03 | 2004-09-15 | Battelle Memorial Institute | Arzneizusammensetzungen zur aerosolbildung und zu inhalationszwecken |
US6428769B1 (en) | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
US6309986B1 (en) | 1999-05-07 | 2001-10-30 | S. C. Johnson & Son, Inc. | Mat for dispensing volatile materials |
KR100752000B1 (ko) | 1999-05-27 | 2007-08-28 | 아쿠스피어 인코포레이티드. | 다공성 약물 매트릭스의 제조방법 |
AU767486B2 (en) | 1999-06-11 | 2003-11-13 | Aradigm Corporation | Method for producing an aerosol |
AU777326B2 (en) | 1999-07-16 | 2004-10-14 | Aradigm Corporation | System for effecting smoke cessation |
EP1210121A2 (de) | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Verbesserung der verabreichung von medikamenten durch und in epitheliale gewebe durch verwendung von oligoarginine-gruppen |
JP2003508501A (ja) | 1999-09-07 | 2003-03-04 | コンジュケム,インコーポレーテッド | 生物学的結合のための肺送達 |
ATE345875T1 (de) | 1999-09-15 | 2006-12-15 | Aradigm Corp | Porenstrukturen zur niederdruckaerosolisierung |
SI1224174T1 (en) | 1999-10-15 | 2003-12-31 | F. Hoffmann-La Roche Ag | Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
HU229310B1 (en) | 1999-10-29 | 2013-10-28 | Nektar Therapeutics | Dry powder compositions having improved dispersivity |
AU1261501A (en) | 1999-12-06 | 2001-06-18 | Stanley L. Gore | Compositions and methods for intranasal delivery of active agents to the brain |
DE19961300A1 (de) | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
EP1941868A3 (de) | 2000-02-28 | 2011-06-29 | PharmaKodex Limited | Verbesserungen an oder im Zusammenhang mit der Verabreichung von oralen Arzneien |
US6632047B2 (en) | 2000-04-14 | 2003-10-14 | Board Of Regents, The University Of Texas System | Heater element for use in an in situ thermal desorption soil remediation system |
JP2001299916A (ja) | 2000-04-18 | 2001-10-30 | Kao Corp | マスク型吸入器 |
EP1292314A2 (de) | 2000-05-23 | 2003-03-19 | The Trustees of Columbia University in the City of New York | Methode zur behandlung von krankheiten der atemwege durch einsatz von glycosaminoglycane |
WO2001095903A1 (en) | 2000-06-15 | 2001-12-20 | Respiratorius Ab | 5-ht3 receptor antagonists for treatment of disorders involving airway constriction |
GB0015981D0 (en) | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
FR2812545B1 (fr) | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur |
US20020117175A1 (en) | 2000-10-27 | 2002-08-29 | Kottayil S. George | Thermal vaporizing device for drug delivery |
US20030121906A1 (en) | 2000-11-29 | 2003-07-03 | Abbott Richard C. | Resistive heaters and uses thereof |
US6799572B2 (en) | 2000-12-22 | 2004-10-05 | Chrysalis Technologies Incorporated | Disposable aerosol generator system and methods for administering the aerosol |
US6491233B2 (en) | 2000-12-22 | 2002-12-10 | Chrysalis Technologies Incorporated | Vapor driven aerosol generator and method of use thereof |
US6501052B2 (en) | 2000-12-22 | 2002-12-31 | Chrysalis Technologies Incorporated | Aerosol generator having multiple heating zones and methods of use thereof |
US6443152B1 (en) | 2001-01-12 | 2002-09-03 | Becton Dickinson And Company | Medicament respiratory delivery device |
FI20010115A0 (fi) | 2001-01-18 | 2001-01-18 | Orion Corp | Menetelmä nanopartikkelien valmistamiseksi |
EP1383376A4 (de) | 2001-03-19 | 2006-03-08 | Praecis Pharm Inc | Pharmazeutische formulierungen für die anhaltende wirkstofffreigabe |
US20030023638A1 (en) * | 2001-05-02 | 2003-01-30 | Weight Christopher F. | Method and apparatus for processing content |
US20030118512A1 (en) | 2001-10-30 | 2003-06-26 | Shen William W. | Volatilization of a drug from an inclusion complex |
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
DE60230035D1 (de) * | 2001-05-24 | 2009-01-08 | Alexza Pharmaceuticals Inc | Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation |
US7090830B2 (en) * | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
WO2002094244A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of benzodiazepines through an inhalation route |
WO2002094234A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of opioids through an inhalation route |
US20080038363A1 (en) | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
WO2002094242A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
US6779520B2 (en) | 2001-10-30 | 2004-08-24 | Iep Pharmaceutical Devices Inc. | Breath actuated dry powder inhaler |
GB0126150D0 (en) | 2001-10-31 | 2002-01-02 | Gw Pharma Ltd | A device method and resistive element for vaporising a substance |
WO2003041693A1 (en) * | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
AU2002363947A1 (en) | 2001-11-21 | 2003-07-24 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
EP1455875A2 (de) | 2001-11-21 | 2004-09-15 | Alexza Molecular Delivery Corporation | Offenzellige substrate für zur arzneimittelverabreichung |
US20030106551A1 (en) | 2001-12-06 | 2003-06-12 | Sprinkel F. Murphy | Resistive heater formed inside a fluid passage of a fluid vaporizing device |
CN1176075C (zh) | 2001-12-07 | 2004-11-17 | 北京燕山石油化工公司研究院 | 吡咯衍生物的制备方法 |
WO2003051367A1 (en) | 2001-12-18 | 2003-06-26 | Alexza Molecular Delivery Corporation | Parental analgesic formulations comprising fentanyl and a cannabinoid receptor agonist |
US6772756B2 (en) | 2002-02-09 | 2004-08-10 | Advanced Inhalation Revolutions Inc. | Method and system for vaporization of a substance |
US6961515B2 (en) | 2002-02-15 | 2005-11-01 | Dekko Technologies, Inc. | PTC heater with flexible printed circuit board |
US20060193788A1 (en) | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
US7074806B2 (en) * | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US6772757B2 (en) | 2002-10-25 | 2004-08-10 | Chrysalis Technologies Incorporated | Concentric controlled temperature profile fluid vaporizing device |
CN1726037B (zh) | 2002-11-26 | 2010-05-05 | 艾利斯达医药品公司 | 抗精神病药用于制备通过吸入传送治疗头痛的药物中的应用 |
US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
CN1717237A (zh) | 2002-11-26 | 2006-01-04 | 艾利斯达分子传输公司 | 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用 |
ATE510174T1 (de) | 2003-05-21 | 2011-06-15 | Alexza Pharmaceuticals Inc | Schlag gezündete unabhängige heizeinheit |
WO2005014090A1 (en) * | 2003-08-04 | 2005-02-17 | Alexza Pharmaceuticals, Inc. | Methods of determining film thicknesses for an aerosol delivery article |
WO2005016421A1 (en) | 2003-08-04 | 2005-02-24 | Alexza Pharmaceuticals, Inc. | Substrates for drug delivery device and methods of preparing and use |
WO2005061033A1 (en) | 2003-12-15 | 2005-07-07 | Alexza Pharmaceuticals, Inc. | Treatment of breakthrough pain by drug aerosol inhalation |
WO2005059804A2 (en) | 2003-12-16 | 2005-06-30 | Alexza Pharmaceuticals, Inc. | Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real-time |
US7402777B2 (en) | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
AU2004322756B2 (en) * | 2004-08-12 | 2011-04-14 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
US20100006092A1 (en) | 2004-08-12 | 2010-01-14 | Alexza Pharmaceuticals, Inc. | Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages |
US20060032496A1 (en) * | 2004-08-12 | 2006-02-16 | Alexza Molecular Delivery Corporation | Inhalation actuated percussive ignition system |
EP1809240A4 (de) | 2004-10-12 | 2010-06-16 | Alexza Pharmaceuticals Inc | Herzsichere schnelle arzneiverabreichung |
US7494344B2 (en) | 2005-12-29 | 2009-02-24 | Molex Incorporated | Heating element connector assembly with press-fit terminals |
WO2008080170A1 (en) | 2006-12-22 | 2008-07-03 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositiions |
US7513781B2 (en) | 2006-12-27 | 2009-04-07 | Molex Incorporated | Heating element connector assembly with insert molded strips |
ES2594867T3 (es) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Unidad de calentamiento para usar en un dispositivo de administración de fármaco |
WO2008134668A2 (en) | 2007-04-27 | 2008-11-06 | Alexza Pharmaceuticals, Inc. | Heat-labile prodrugs |
WO2009089550A1 (en) | 2008-01-11 | 2009-07-16 | Alexza Pharmaceuticals, Inc. | Metal coordination complexes of volatile drugs |
US7834295B2 (en) | 2008-09-16 | 2010-11-16 | Alexza Pharmaceuticals, Inc. | Printable igniters |
US20100065052A1 (en) | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Heating Units |
US20100068155A1 (en) | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Reactant Formulations and Methods for Controlled Heating |
US20100300433A1 (en) | 2009-05-28 | 2010-12-02 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
US20100181387A1 (en) | 2009-12-01 | 2010-07-22 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US20120048963A1 (en) | 2010-08-26 | 2012-03-01 | Alexza Pharmaceuticals, Inc. | Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter |
EP3019154B1 (de) | 2013-07-11 | 2020-09-02 | Alexza Pharmaceuticals, Inc. | Nikotinsalz mit meta-salicylsäure |
-
2001
- 2001-10-26 US US10/057,198 patent/US20030051728A1/en not_active Abandoned
- 2001-10-26 US US10/057,197 patent/US7766013B2/en not_active Expired - Fee Related
-
2002
- 2002-05-13 CN CNB028114078A patent/CN100496458C/zh not_active Expired - Lifetime
- 2002-05-13 AT AT02739267T patent/ATE468105T1/de not_active IP Right Cessation
- 2002-05-13 PL PL02374048A patent/PL374048A1/xx not_active Application Discontinuation
- 2002-05-13 JP JP2003501429A patent/JP4510438B2/ja not_active Expired - Lifetime
- 2002-05-13 HU HU0401008A patent/HUP0401008A2/hu unknown
- 2002-05-13 MX MXPA03011268A patent/MXPA03011268A/es active IP Right Grant
- 2002-05-13 DE DE60239604T patent/DE60239604D1/de not_active Expired - Lifetime
- 2002-05-13 CA CA2447081A patent/CA2447081C/en not_active Expired - Lifetime
- 2002-05-13 AU AU2002311926A patent/AU2002311926B2/en not_active Expired
- 2002-05-13 AU AU2002311923A patent/AU2002311923B2/en not_active Expired
- 2002-05-13 IL IL15895502A patent/IL158955A0/xx unknown
- 2002-05-13 ES ES02739267T patent/ES2343678T3/es not_active Expired - Lifetime
- 2002-05-13 EP EP02742015A patent/EP1392263A2/de not_active Withdrawn
- 2002-05-13 CA CA2646756A patent/CA2646756C/en not_active Expired - Lifetime
- 2002-05-13 NZ NZ529296A patent/NZ529296A/en unknown
- 2002-05-13 JP JP2003501533A patent/JP4912566B2/ja not_active Expired - Fee Related
- 2002-05-13 US US10/146,088 patent/US7537009B2/en active Active
- 2002-05-13 MX MXPA03011269A patent/MXPA03011269A/es active IP Right Grant
- 2002-05-13 DE DE60236430T patent/DE60236430D1/de not_active Expired - Lifetime
- 2002-05-13 AT AT02739262T patent/ATE503516T1/de not_active IP Right Cessation
- 2002-05-13 EP EP02739262A patent/EP1392381B9/de not_active Expired - Lifetime
- 2002-05-13 CZ CZ20033223A patent/CZ20033223A3/cs unknown
- 2002-05-13 HU HU0401948A patent/HUP0401948A3/hu unknown
- 2002-05-13 EP EP02739267A patent/EP1392242B1/de not_active Expired - Lifetime
- 2002-05-13 WO PCT/US2002/015425 patent/WO2002098389A1/en active Application Filing
- 2002-05-13 WO PCT/US2002/015363 patent/WO2002098496A1/en active IP Right Grant
- 2002-05-13 PL PL02373836A patent/PL373836A1/xx unknown
- 2002-05-13 JP JP2003501430A patent/JP2004532881A/ja active Pending
- 2002-05-13 WO PCT/US2002/018608 patent/WO2002098390A2/en active Application Filing
- 2002-05-13 US US10/146,080 patent/US7942147B2/en not_active Expired - Fee Related
- 2002-05-13 US US10/146,515 patent/US6682716B2/en not_active Expired - Fee Related
- 2002-05-13 CA CA002447354A patent/CA2447354C/en not_active Expired - Lifetime
- 2002-05-13 CZ CZ20033249A patent/CZ20033249A3/cs unknown
- 2002-05-13 NZ NZ529298A patent/NZ529298A/en unknown
- 2002-05-13 CN CNB02811406XA patent/CN1304067C/zh not_active Expired - Lifetime
- 2002-05-13 CA CA002447210A patent/CA2447210C/en not_active Expired - Fee Related
- 2002-05-13 IL IL15895402A patent/IL158954A0/xx unknown
-
2003
- 2003-10-30 US US10/696,959 patent/US20040096402A1/en not_active Abandoned
-
2005
- 2005-01-14 HK HK05100362A patent/HK1068293A1/xx not_active IP Right Cessation
- 2005-01-18 HK HK05100459.9A patent/HK1068268A1/xx not_active IP Right Cessation
-
2007
- 2007-08-16 AU AU2007207865A patent/AU2007207865B2/en not_active Expired
- 2007-10-30 AU AU2007231750A patent/AU2007231750B2/en not_active Expired
-
2009
- 2009-05-22 US US12/471,070 patent/US8074644B2/en not_active Expired - Fee Related
- 2009-11-12 JP JP2009259070A patent/JP2010057950A/ja active Pending
-
2010
- 2010-07-30 US US12/847,584 patent/US9308208B2/en not_active Expired - Fee Related
-
2011
- 2011-04-01 US US13/078,600 patent/US20110240022A1/en not_active Abandoned
- 2011-04-01 US US13/078,606 patent/US20110240013A1/en not_active Abandoned
-
2013
- 2013-03-27 US US13/851,577 patent/US8955512B2/en not_active Expired - Fee Related
- 2013-11-11 US US14/077,015 patent/US9439907B2/en not_active Expired - Lifetime
- 2013-11-13 US US14/078,577 patent/US9687487B2/en not_active Expired - Lifetime
-
2015
- 2015-02-17 US US14/624,311 patent/US20150157635A1/en not_active Abandoned
-
2017
- 2017-06-26 US US15/633,508 patent/US11065400B2/en not_active Expired - Lifetime
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1803334A (en) * | 1931-05-05 | Ootthujp lehmann | ||
US1864980A (en) * | 1932-06-28 | Vapobizeb | ||
US2243669A (en) * | 1941-05-27 | Electrical vaporizer | ||
US3080624A (en) * | 1963-03-12 | weber iii | ||
US1535486A (en) * | 1922-08-28 | 1925-04-28 | James W Lundy | Electric-lamp bulb |
US2309846A (en) * | 1941-03-06 | 1943-02-02 | Holm Einar Marius | Inhaler |
US2469656A (en) * | 1946-04-19 | 1949-05-10 | Peter H Lienert | Vaporizer |
US2887106A (en) * | 1956-09-27 | 1959-05-19 | Robinson Joseph | Combined vaporizer and cover for medicament jar |
US3433791A (en) * | 1960-09-05 | 1969-03-18 | Reckitt & Sons Ltd | Endoethano nor oripavines and nor thebaines |
US3164600A (en) * | 1961-10-10 | 1965-01-05 | Res Lab Dr C Janssen N V | 1-aralkyl-4-(n-aryl-carbonyl amino)-piperidines and related compounds |
US3169095A (en) * | 1962-10-30 | 1965-02-09 | Rexall Drug Chemical | Self-propelling powder-dispensing compositions |
US3560607A (en) * | 1962-11-30 | 1971-02-02 | Fisons Pharmaceuticals Ltd | Aerosol formulations of finely divided solid medicaments with anionic surface-active agents |
US3949743A (en) * | 1973-03-19 | 1976-04-13 | Schick Incorporated | Medicated vapor production method and apparatus |
US3930796A (en) * | 1973-09-13 | 1976-01-06 | Universal Oil Products Company | Catalytic fume control device |
US4020379A (en) * | 1975-10-02 | 1977-04-26 | Eg&G, Inc. | Bulb-shaped flashtube with metal envelope |
US4184099A (en) * | 1977-04-27 | 1980-01-15 | International Flavors & Fragrances Inc. | Composition for slow release of volatile ingredients at _high temperature; and article comprising same |
US4183912A (en) * | 1978-01-16 | 1980-01-15 | American Home Products Corporation | Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine |
US4276243A (en) * | 1978-12-08 | 1981-06-30 | Western Electric Company, Inc. | Vapor delivery control system and method |
US4588721A (en) * | 1983-09-12 | 1986-05-13 | The Upjohn Company | Treatment of negative symptoms of schizophrenia |
US4647428A (en) * | 1984-06-04 | 1987-03-03 | Gyulay Joseph M | Air freshener method |
US4647433A (en) * | 1984-10-01 | 1987-03-03 | Donald Spector | Long-life aroma-generating capsule |
US4722334A (en) * | 1985-07-16 | 1988-02-02 | Transpirator Technologies, Inc. | Method and apparatus for pulmonary and cardiovascular conditioning of racehorses and competition animals |
US4735358A (en) * | 1986-03-04 | 1988-04-05 | Daiken Iko Kabushiki Kaisha | Method and apparatus of vaporizing active substances |
US4924883A (en) * | 1987-03-06 | 1990-05-15 | R. J. Reynolds Tobacco Company | Smoking article |
US5017575A (en) * | 1987-06-09 | 1991-05-21 | Golwyn Daniel H | Treatment of immunologically based disorders, specifically Crohn's disease |
US4935624A (en) * | 1987-09-30 | 1990-06-19 | Cornell Research Foundation, Inc. | Thermal-assisted electrospray interface (TAESI) for LC/MS |
US4911157A (en) * | 1988-01-07 | 1990-03-27 | Pegasus Research Corporation | Self-regulating, heated nebulizer system |
US5112598A (en) * | 1988-05-04 | 1992-05-12 | Hermes Fabrik Pharmazeutischer Preparate Franz Gradinger Gmbh & Co. Kg | Vitamin a aerosol-inhalate preparations |
US4984158A (en) * | 1988-10-14 | 1991-01-08 | Hillsman Dean | Metered dose inhaler biofeedback training and evaluation system |
US4892109A (en) * | 1989-03-08 | 1990-01-09 | Brown & Williamson Tobacco Corporation | Simulated smoking article |
US5093894A (en) * | 1989-12-01 | 1992-03-03 | Philip Morris Incorporated | Electrically-powered linear heating element |
US5408574A (en) * | 1989-12-01 | 1995-04-18 | Philip Morris Incorporated | Flat ceramic heater having discrete heating zones |
US5109180A (en) * | 1989-12-14 | 1992-04-28 | Phillips Petroleum Company | Apparatus providing a shatter-resistant electric lamp |
US5126123A (en) * | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
US5592934A (en) * | 1990-08-02 | 1997-01-14 | The Boc Group Plc | Anaesthetic vaporizer |
US5179966A (en) * | 1990-11-19 | 1993-01-19 | Philip Morris Incorporated | Flavor generating article |
US5095921A (en) * | 1990-11-19 | 1992-03-17 | Philip Morris Incorporated | Flavor generating article |
US6051566A (en) * | 1991-02-09 | 2000-04-18 | B.S.D. Bio Science Development Snc Di Omini C. & Zuccari G. | Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation |
US5865185A (en) * | 1991-03-11 | 1999-02-02 | Philip Morris Incorporated | Flavor generating article |
US5505214A (en) * | 1991-03-11 | 1996-04-09 | Philip Morris Incorporated | Electrical smoking article and method for making same |
US5613504A (en) * | 1991-03-11 | 1997-03-25 | Philip Morris Incorporated | Flavor generating article and method for making same |
US5186164A (en) * | 1991-03-15 | 1993-02-16 | Puthalath Raghuprasad | Mist inhaler |
US5402517A (en) * | 1991-05-01 | 1995-03-28 | Reckitt & Colman Products Limited | Apparatus for emitting a volatile chemical agent by heating and means for adjusting a spacing between a heater and the chemical agent to regulate the rate of vaporization |
US5285798A (en) * | 1991-06-28 | 1994-02-15 | R. J. Reynolds Tobacco Company | Tobacco smoking article with electrochemical heat source |
US5593792A (en) * | 1991-06-28 | 1997-01-14 | R. J. Reynolds Tobacco Company | Electrochemical heat source |
US5322075A (en) * | 1992-09-10 | 1994-06-21 | Philip Morris Incorporated | Heater for an electric flavor-generating article |
US5613505A (en) * | 1992-09-11 | 1997-03-25 | Philip Morris Incorporated | Inductive heating systems for smoking articles |
US5894841A (en) * | 1993-06-29 | 1999-04-20 | Ponwell Enterprises Limited | Dispenser |
US5479948A (en) * | 1993-08-10 | 1996-01-02 | Philip Morris Incorporated | Electrical smoking article having continuous tobacco flavor web and flavor cassette therefor |
US5400969A (en) * | 1993-09-20 | 1995-03-28 | Keene; Christopher M. | Liquid vaporizer and diffuser |
US5605146A (en) * | 1993-11-29 | 1997-02-25 | Instrumentarium Oy | Method and an arrangement in connection with vaporizing an anaesthetic |
US5767117A (en) * | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
US5738865A (en) * | 1995-04-07 | 1998-04-14 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US5904900A (en) * | 1995-04-28 | 1999-05-18 | Etat Francais As Represented By Le Delegue General Pour L'armement | Device for sampling gaseous substances, liquids, aerosols or even powdered materials for in situ analysis |
US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
US6561186B2 (en) * | 1995-08-02 | 2003-05-13 | Innovative Devices | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
US5591409A (en) * | 1995-08-15 | 1997-01-07 | Watkins; Carl J. | Providing aromas |
US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
US5743251A (en) * | 1996-05-15 | 1998-04-28 | Philip Morris Incorporated | Aerosol and a method and apparatus for generating an aerosol |
US6694975B2 (en) * | 1996-11-21 | 2004-02-24 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US6050260A (en) * | 1996-12-02 | 2000-04-18 | Fisher & Paykel Limited | Humidifier sleep apnea treatment apparatus |
US5769621A (en) * | 1997-05-23 | 1998-06-23 | The Regents Of The University Of California | Laser ablation based fuel ignition |
US5874841A (en) * | 1997-07-28 | 1999-02-23 | Philips Electronics North America Corporation | Sample-and-hold circuit for a switched-mode power supply |
US6390453B1 (en) * | 1997-10-22 | 2002-05-21 | Microfab Technologies, Inc. | Method and apparatus for delivery of fragrances and vapors to the nose |
US20020037828A1 (en) * | 1997-10-28 | 2002-03-28 | Wilson Leland F. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US6178969B1 (en) * | 1998-03-03 | 2001-01-30 | Brown & Williamson Tobacco Corporation | Aerosol delivery smoking article |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US6516796B1 (en) * | 1998-10-14 | 2003-02-11 | Chrysalis Technologies Incorporated | Aerosol generator and methods of making and using an aerosol generator |
US6557552B1 (en) * | 1998-10-14 | 2003-05-06 | Chrysalis Technologies Incorporated | Aerosol generator and methods of making and using an aerosol generator |
US20020031480A1 (en) * | 1998-10-27 | 2002-03-14 | Joanne Peart | Delta9 tetrahydrocannabinol (Delta9 THC) solution metered dose inhalers and methods of use |
US6376550B1 (en) * | 1999-02-09 | 2002-04-23 | Asta Medica Ag | Pharmaceutical compositions containing tramadol for migraine |
US6053176A (en) * | 1999-02-23 | 2000-04-25 | Philip Morris Incorporated | Heater and method for efficiently generating an aerosol from an indexing substrate |
US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US6506762B1 (en) * | 1999-09-30 | 2003-01-14 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
US20030049025A1 (en) * | 2000-01-13 | 2003-03-13 | Hermann Neumann | Chip that comprises an active agent and an integrated heating element |
US6688313B2 (en) * | 2000-03-23 | 2004-02-10 | Philip Morris Incorporated | Electrical smoking system and method |
US20040016427A1 (en) * | 2000-04-27 | 2004-01-29 | Byron Peter R. | Method and apparatus for generating an aerosol |
US6514482B1 (en) * | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US20020058009A1 (en) * | 2000-09-19 | 2002-05-16 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6681998B2 (en) * | 2000-12-22 | 2004-01-27 | Chrysalis Technologies Incorporated | Aerosol generator having inductive heater and method of use thereof |
US6701921B2 (en) * | 2000-12-22 | 2004-03-09 | Chrysalis Technologies Incorporated | Aerosol generator having heater in multilayered composite and method of use thereof |
US6680668B2 (en) * | 2001-01-19 | 2004-01-20 | Vishay Intertechnology, Inc. | Fast heat rise resistor using resistive foil |
US6671945B2 (en) * | 2001-01-19 | 2004-01-06 | Vishay Intertechnology, Inc. | Method for making a resistor using resistive foil |
US20030004142A1 (en) * | 2001-04-18 | 2003-01-02 | Prior Christopher P. | Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway |
US6737042B2 (en) * | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US20070028916A1 (en) * | 2001-05-24 | 2007-02-08 | Hale Ron L | Rapid-heating drug delivery article and method of use |
US20070031340A1 (en) * | 2001-05-24 | 2007-02-08 | Hale Ron L | Thin-film drug delivery article and method of use |
US20070014737A1 (en) * | 2001-05-24 | 2007-01-18 | Alexza Pharmaceuticals, Inc. | Delivery of muscle relaxants through an inhalation route |
US20030033055A1 (en) * | 2001-07-31 | 2003-02-13 | Mcrae Douglas D. | Method and apparatus for generating a volatilized liquid |
US6715487B2 (en) * | 2001-09-21 | 2004-04-06 | Chrysalis Technologies Incorporated | Dual capillary fluid vaporizing device |
US6568390B2 (en) * | 2001-09-21 | 2003-05-27 | Chrysalis Technologies Incorporated | Dual capillary fluid vaporizing device |
US20040055504A1 (en) * | 2001-10-15 | 2004-03-25 | Lee Brian Craig | Electro-thermal odor-releasing inks and methods for releasing odors from the same |
US6681769B2 (en) * | 2001-12-06 | 2004-01-27 | Crysalis Technologies Incorporated | Aerosol generator having a multiple path heater arrangement and method of use thereof |
US6701922B2 (en) * | 2001-12-20 | 2004-03-09 | Chrysalis Technologies Incorporated | Mouthpiece entrainment airflow control for aerosol generators |
US6728478B2 (en) * | 2002-02-21 | 2004-04-27 | Dekko Heating Technologies, Inc. | Heated chemical delivery system |
US20040009128A1 (en) * | 2002-05-13 | 2004-01-15 | Rabinowitz Joshua D | Delivery of drug amines through an inhalation route |
US20040035409A1 (en) * | 2002-06-06 | 2004-02-26 | Harwig Jeffrey L. | Localized surface volatilization |
US20040081624A1 (en) * | 2002-09-06 | 2004-04-29 | Chrysalis Technologies Incorporated | Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols |
US20040099266A1 (en) * | 2002-11-27 | 2004-05-27 | Stephen Cross | Inhalation device for producing a drug aerosol |
Cited By (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10350157B2 (en) | 2001-05-24 | 2019-07-16 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US20060216244A1 (en) * | 2001-05-24 | 2006-09-28 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of parkinson's through an inhalation route |
US20090246147A1 (en) * | 2001-05-24 | 2009-10-01 | Alexza Pharmaceuticals, Inc. | Delivery Of Antipsychotics Through An Inhalation Route |
US9211382B2 (en) | 2001-05-24 | 2015-12-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US20080311176A1 (en) * | 2001-05-24 | 2008-12-18 | Alexza Pharmaceuticals, Inc. | Drug Condensation Aerosols And Kits |
US8235037B2 (en) | 2001-05-24 | 2012-08-07 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US8173107B2 (en) | 2001-05-24 | 2012-05-08 | Alexza Pharmaceuticals, Inc. | Delivery of antipsychotics through an inhalation route |
US20070178052A1 (en) * | 2001-05-24 | 2007-08-02 | Alexza Pharmaceuticals, Inc. | Delivery of opioids through an inhalation route |
US7988952B2 (en) | 2001-05-24 | 2011-08-02 | Alexza Pharmaceuticals, Inc. | Delivery of drug esters through an inhalation route |
US20070014737A1 (en) * | 2001-05-24 | 2007-01-18 | Alexza Pharmaceuticals, Inc. | Delivery of muscle relaxants through an inhalation route |
US20060153779A1 (en) * | 2001-05-24 | 2006-07-13 | Alexza Pharmaceuticals, Inc. | Delivery of stimulants through an inhalation route |
US20060280692A1 (en) * | 2001-05-24 | 2006-12-14 | Alexza Pharmaceuticals, Inc. | Delivery of antipsychotics through an inhalation route |
US20060216243A1 (en) * | 2001-05-24 | 2006-09-28 | Alexza Pharmaceuticals, Inc. | Delivery of Beta-Blockers Through An Inhalation Route |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US20060233718A1 (en) * | 2001-05-24 | 2006-10-19 | Alexza Pharmaceuticals, Inc. | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
US20060239936A1 (en) * | 2001-05-24 | 2006-10-26 | Alexza Pharmaceuticals, Inc. | Delivery of anti-migraine compounds through an inhalation route |
US20060246012A1 (en) * | 2001-05-24 | 2006-11-02 | Alexza Pharmaceuticals, Inc. | Delivery of physiologically active compounds through an inhalation route |
US9440034B2 (en) | 2001-05-24 | 2016-09-13 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US20060251587A1 (en) * | 2001-05-24 | 2006-11-09 | Alexza Pharmaceuticals, Inc. | Delivery of analgesics through an inhalation route |
US20060251588A1 (en) * | 2001-05-24 | 2006-11-09 | Alexza Pharmaceuticals, Inc. | Delivery of erectile dysfunction drugs through an inhalation route |
US20060286043A1 (en) * | 2001-05-24 | 2006-12-21 | Alexza Pharmaceuticals, Inc. | Delivery of antihistamines through an inhalation route |
US20060257329A1 (en) * | 2001-05-24 | 2006-11-16 | Alexza Pharmaceuticals, Inc. | Delivery of drug esters through an inhalation route |
US20060269487A1 (en) * | 2001-05-24 | 2006-11-30 | Alexza Pharmaceuticals, Inc. | Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
US7942147B2 (en) | 2001-06-05 | 2011-05-17 | Alexza Pharmaceuticals, Inc. | Aerosol forming device for use in inhalation therapy |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US9687487B2 (en) | 2001-06-05 | 2017-06-27 | Alexza Pharmaceuticals, Inc. | Aerosol forming device for use in inhalation therapy |
US9439907B2 (en) | 2001-06-05 | 2016-09-13 | Alexza Pharmaceutical, Inc. | Method of forming an aerosol for inhalation delivery |
US20030062042A1 (en) * | 2001-06-05 | 2003-04-03 | Wensley Martin J. | Aerosol generating method and device |
US8074644B2 (en) | 2001-06-05 | 2011-12-13 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US11065400B2 (en) | 2001-06-05 | 2021-07-20 | Alexza Pharmaceuticals, Inc. | Aerosol forming device for use in inhalation therapy |
US9308208B2 (en) | 2001-06-05 | 2016-04-12 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US8955512B2 (en) | 2001-06-05 | 2015-02-17 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US20060257328A1 (en) * | 2001-11-21 | 2006-11-16 | Alexza Pharmaceuticals, Inc. | Delivery of caffeine through an inhalation route |
US7987846B2 (en) | 2002-05-13 | 2011-08-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20040009128A1 (en) * | 2002-05-13 | 2004-01-15 | Rabinowitz Joshua D | Delivery of drug amines through an inhalation route |
US8003080B2 (en) | 2002-05-13 | 2011-08-23 | Alexza Pharmaceuticals, Inc. | Delivery of drug amines through an inhalation route |
US20030209240A1 (en) * | 2002-05-13 | 2003-11-13 | Hale Ron L. | Method and apparatus for vaporizing a compound |
US20100055048A1 (en) * | 2002-05-20 | 2010-03-04 | Alexza Pharmaceuticals, Inc. | Acute treatment of headache with phenothiazine antipsychotics |
US8288372B2 (en) | 2002-11-26 | 2012-10-16 | Alexza Pharmaceuticals, Inc. | Method for treating headache with loxapine |
US7981401B2 (en) | 2002-11-26 | 2011-07-19 | Alexza Pharmaceuticals, Inc. | Diuretic aerosols and methods of making and using them |
US20040102434A1 (en) * | 2002-11-26 | 2004-05-27 | Alexza Molecular Delivery Corporation | Method for treating pain with loxapine and amoxapine |
US20040105819A1 (en) * | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Respiratory drug condensation aerosols and methods of making and using them |
US8506935B2 (en) | 2002-11-26 | 2013-08-13 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US20090062254A1 (en) * | 2002-11-26 | 2009-03-05 | Alexza Pharmaceuticals, Inc. | Acute Treatment of Headache with Phenothiazine Antipsychotics |
US20090258075A1 (en) * | 2002-11-26 | 2009-10-15 | Alexza Pharmaceuticals, Inc. | Respiratory Drug Condensation Aerosols and Methods of Making and Using Them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
WO2004096118A2 (en) | 2003-04-29 | 2004-11-11 | Neurim Pharmaceuticals (1991) Ltd. | Composition for improving cognition and memory |
US20060229340A1 (en) * | 2003-04-29 | 2006-10-12 | Neurim Pharmaceuticals (1991) Ltd. | Composition for improving cognition and memory |
US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
US8859593B2 (en) | 2003-04-29 | 2014-10-14 | Neurim Pharmaceuticals (1991) Ltd. | Composition for improving cognition and memory |
US20050079166A1 (en) * | 2003-05-21 | 2005-04-14 | Alexza Molecular Delivery Corporation | Self-contained heating unit and drug-supply unit employing same |
US9370629B2 (en) | 2003-05-21 | 2016-06-21 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US8387612B2 (en) | 2003-05-21 | 2013-03-05 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US20040234916A1 (en) * | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
US8991387B2 (en) | 2003-05-21 | 2015-03-31 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US20180296568A1 (en) * | 2003-08-04 | 2018-10-18 | Alexza Pharmaceuticals, Inc. | Substrates for Drug Delivery Device and Methods of Preparing and Use |
US20050034723A1 (en) * | 2003-08-04 | 2005-02-17 | Bryson Bennett | Substrates for drug delivery device and methods of preparing and use |
US20140072605A1 (en) * | 2003-08-04 | 2014-03-13 | Alexza Pharmaceuticals, Inc. | Substrates for Drug Delivery Device and Methods of Preparing and Use |
WO2005053444A1 (de) * | 2003-12-05 | 2005-06-16 | Lts Lohmann Therapie-Systeme Ag | Inhalator für basische pharmazeutische wirkstoffe sowie verfahren für dessen herstellung |
US7923662B2 (en) | 2004-05-20 | 2011-04-12 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US8333197B2 (en) | 2004-06-03 | 2012-12-18 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US20060251810A1 (en) * | 2005-05-03 | 2006-11-09 | Eastman Kodak Company | Metering material to promote rapid vaporization |
US7213347B2 (en) * | 2005-05-03 | 2007-05-08 | Eastman Kodak Company | Metering material to promote rapid vaporization |
US20090107495A1 (en) * | 2005-07-21 | 2009-04-30 | National Institute For Materials Science | Device for inhalation of medicine |
US20070070612A1 (en) * | 2005-09-23 | 2007-03-29 | Bull, S.A.S. | System for maintaining an assembly of three parts in position that exerts a predetermined compressive force on the itermediate part |
US20070155255A1 (en) * | 2005-12-29 | 2007-07-05 | Charles Galauner | Heating element connector assembly with press-fit terminals |
US7494344B2 (en) | 2005-12-29 | 2009-02-24 | Molex Incorporated | Heating element connector assembly with press-fit terminals |
US20080299048A1 (en) * | 2006-12-22 | 2008-12-04 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositions |
US7513781B2 (en) | 2006-12-27 | 2009-04-07 | Molex Incorporated | Heating element connector assembly with insert molded strips |
US10625033B2 (en) | 2007-03-09 | 2020-04-21 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US11642473B2 (en) | 2007-03-09 | 2023-05-09 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US7834295B2 (en) | 2008-09-16 | 2010-11-16 | Alexza Pharmaceuticals, Inc. | Printable igniters |
US20100068154A1 (en) * | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Printable Igniters |
US20100065052A1 (en) * | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Heating Units |
US20230355515A1 (en) * | 2009-05-28 | 2023-11-09 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
US20100300433A1 (en) * | 2009-05-28 | 2010-12-02 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
US20190021987A1 (en) * | 2009-05-28 | 2019-01-24 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
US11839714B2 (en) | 2010-08-26 | 2023-12-12 | Alexza Pharmaceuticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
US11484668B2 (en) | 2010-08-26 | 2022-11-01 | Alexza Pharmauceticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
US10786635B2 (en) | 2010-08-26 | 2020-09-29 | Alexza Pharmaceuticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
US10034988B2 (en) | 2012-11-28 | 2018-07-31 | Fontem Holdings I B.V. | Methods and devices for compound delivery |
WO2014085719A1 (en) * | 2012-11-28 | 2014-06-05 | E-Nicotine Technology, Inc. | Methods and devices for compound delivery |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US8889190B2 (en) | 2013-03-13 | 2014-11-18 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10363224B2 (en) | 2013-03-13 | 2019-07-30 | Upsher-Smith Laboratories, Llc | Extended-release topiramate capsules |
US9555005B2 (en) | 2013-03-15 | 2017-01-31 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10172878B2 (en) | 2013-03-15 | 2019-01-08 | Upsher-Smith Laboratories, Llc | Extended-release topiramate capsules |
US10166224B2 (en) | 2013-07-11 | 2019-01-01 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid and applications therein |
US9724341B2 (en) | 2013-07-11 | 2017-08-08 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid |
US11458130B2 (en) | 2013-07-11 | 2022-10-04 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid and applications therein |
US10194693B2 (en) | 2013-09-20 | 2019-02-05 | Fontem Holdings 1 B.V. | Aerosol generating device |
US11511054B2 (en) | 2015-03-11 | 2022-11-29 | Alexza Pharmaceuticals, Inc. | Use of antistatic materials in the airway for thermal aerosol condensation process |
EP3313213B1 (de) | 2015-06-29 | 2021-03-10 | Nicoventures Trading Limited | Elektronisches aerosolbereitstellungssystem |
US11241383B2 (en) | 2016-12-09 | 2022-02-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
US11717479B2 (en) | 2016-12-09 | 2023-08-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
AU2018294501B2 (en) * | 2017-06-30 | 2023-08-17 | Philip Morris Products S.A. | Aerosol-generating device and aerosol-generating system with inductive heating system with efficient power control |
EP3646669B1 (de) | 2017-06-30 | 2021-07-28 | Philip Morris Products S.A. | Aerosolerzeugungsvorrichtung und aerosolerzeugungssystem mit induktionsheizsystem mit effizienter leistungsregelung |
US10506830B2 (en) | 2017-09-22 | 2019-12-17 | Altria Client Services Llc | Air flow design for an e-vaping cartridge, method of making the e-vaping cartridge, and e-vaping device including the cartridge |
US11317651B2 (en) | 2017-09-22 | 2022-05-03 | Altria Client Services Llc | Cartridge with dilution air passage, method of making the cartridge, and e-vaping device including the cartridge |
US20230414314A1 (en) * | 2017-10-02 | 2023-12-28 | Lightlab Imaging, Inc. | Intravascular Data Collection Probes And Related Assemblies |
US11447510B2 (en) | 2017-10-09 | 2022-09-20 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11180517B2 (en) | 2017-10-09 | 2021-11-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10947257B2 (en) | 2017-10-09 | 2021-03-16 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11939346B2 (en) | 2017-10-09 | 2024-03-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11629159B2 (en) | 2017-10-09 | 2023-04-18 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11149044B2 (en) | 2017-10-09 | 2021-10-19 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10954259B1 (en) | 2017-10-09 | 2021-03-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11851451B2 (en) | 2017-10-09 | 2023-12-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11505564B2 (en) | 2017-10-09 | 2022-11-22 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11260195B2 (en) | 2018-09-20 | 2022-03-01 | General Electric Company | Systems and methods for an inductively heated anesthetic vaporizer |
WO2020060992A1 (en) * | 2018-09-20 | 2020-03-26 | General Electric Company | Systems and methods for an inductively heated anesthetic vaporizer |
US11738035B2 (en) | 2019-04-17 | 2023-08-29 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
US11865126B2 (en) | 2019-04-17 | 2024-01-09 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
US12036074B2 (en) | 2022-05-23 | 2024-07-16 | Lightlab Imaging, Inc. | Intravascular data collection probes and related assemblies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7766013B2 (en) | Aerosol generating method and device | |
AU2002311926A1 (en) | Method of forming an aerosol for inhalation delivery | |
AU2002311923A1 (en) | An aerosol forming device for use in inhalation therapy | |
WO1994009842A1 (en) | Method and devices for delivering drugs by inhalation | |
ES2361908T3 (es) | Un dispositivo formador de aerosol para uso en terapia de inhalación. | |
Menon et al. | Pulmonary, Nasal, and Topical Aerosol Drug Delivery Systems | |
Usmani | Delivery of drugs to the airways | |
Ding | Inhalation: Liquids | |
AU2002315076A1 (en) | Delivery of aerosols containing small particles through an inhalation route |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALEXZA MOLECULAR DELIVERY CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LLOYD, PETER M.;WENSLEY, MARTIN J.;MUFSON, DANIEL;AND OTHERS;REEL/FRAME:013285/0525;SIGNING DATES FROM 20020828 TO 20020905 |
|
AS | Assignment |
Owner name: ALEXZA PHARMACEUTICALS, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:ALEXZA MOLECULAR DELIVERY CORPORATION;REEL/FRAME:016926/0674 Effective date: 20050720 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |